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ABSTRACT OF THE DISSERTATION 
CANCER THERAPY COMBINING THE MODALITIES OF HYPERTHERMIA AND 
CHEMOTHERAPY: IN VITRO CELLULAR RESPONSE AFTER RAPID HEAT 
ACCUMULATION IN THE CANCER CELL 
by 
Yuan Tang 
Florida International University, 2010 
Miami, Florida 
Professor Anthony J. McGoron, Major Professor 
Hyperthermia is usually used at a sub-lethal level in cancer treatment to potentiate the 
effects of chemotherapy. The purpose of this study is to investigate the role of heating 
rate in achieving synergistic cell killing by chemotherapy and hyperthermia. For this 
purpose, in vitro cell culture experiments with a uterine cancer cell line (MES-SA) and its 
multidrug resistant (MDR) variant MES-SA/Dx5 were conducted. The cytotoxicitiy, 
mode of cell death, induction of thermal tolerance and P-gp mediated MDR following the 
two different modes of heating were studied. Doxorubicin (DOX) was used as the 
chemotherapy drug. Indocyanine green (ICG), which absorbs near infrared light at 
808nm (ideal for tissue penetration), was chosen for achieving rapid rate hyperthermia. A 
slow rate hyperthermia was provided by a cell culture incubator. The results show that 
the potentiating effect of hyperthermia to chemotherapy can be maximized by increasing 
the rate of heating as evident by the results from the cytotoxicity assay. When delivered 
at the same thermal dose, a rapid increase in temperature from 37 °C to 43 °C caused 
more cell membrane damage than gradually heating the cells from 37 °C to 43 °C and 
 vi
thus allowed for more intracellular accumulation of the chemotherapeutic agents. 
Different modes of cell death are observed by the two hyperthermia delivery methods. 
The rapid rate laser-ICG hyperthermia @ 43 °C caused cell necrosis whereas the slow 
rate incubator hyperthermia @ 43 °C induced very mild apoptosis. At 43 °C a positive 
correlation between thermal tolerance and the length of hyperthermia exposure is 
identified. This study shows that by increasing the rate of heating, less thermal dose is 
needed in order to overcome P-gp mediated MDR. 
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I. INTRODUCTION 
Hyperthermia (thermal therapy or thermotherapy) could be used for cancer treatment 
where high temperature (up to 45°C) is applied to body tissue. Research has shown that 
hyperthermia can kill cancer cells by exerting protein or structure damage within cells [1]. 
An advantage of using hyperthermia to kill cancer cells is that usually normal tissues or 
cells are not as susceptible to high temperature as are cancerous tissues [2]. Thus, 
hyperthermia may shrink tumors with minimum injury to the surrounding healthy tissues.  
Although hyperthermia’s encouraging potential on cancer treatment has been shown in a 
large number of clinical trials, its exact mechanism of action is still somewhat unclear [3, 
4]. In pre-clinical investigations such as in vitro cell culture experiments and animal 
studies, the cell killing effect of hyperthermia was found to be highly thermal dose 
dependent, although a correlation between temperature and response rate was achieved 
within a broad range of temperatures from 41°C to 47°C [5-7]. On the one hand, 
treatment outcome varied greatly among cancer types and among different cancer cell 
lines even in the same hyperthermia settings while on the other hand, small changes in 
hyperthermia settings could lead to huge difference in the treatment outcome, such as the 
rate of temperature change, exposure duration, and means of heat delivery. Since all these 
uncertainties and variations in the hyperthermia treatment, recent research interests have 
been shifted to the molecular and cellular targets of hyperthermia as well as the action 
mechanism of hyperthermia in the cellular and molecular level. 
In this study, a chemotherapy-hyperthermia combinational cancer treatment regime was 
studied; various parameters that could influence the final treatment outcome were studied 
by in vitro cell culture experiments. The cell killing/growth inhibition effect was assessed 
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with two different hyperthermia delivery approaches in two cancer cell lines. Through 
this comparative study, we try to understand the cellular and molecular basis of 
hyperthermia in this combinational treatment regime, therefore giving a plausible 
explanation to those effects we have observed, such as thermal chemosensitization. In 
this respect, the study focuses on the distinct cellular and molecular events following 
hyperthermia, particularly those that participated in protein expression and cell death 
pathways induced by hyperthermia chemotherapy interaction.  
1. Biological Response Following Hyperthermia  
The cancer cell killing/growth inhibition ability of hyperthermia has been reported in 
numerous in vivo and in vitro studies [8-10]. Some research showed moderate 
hyperthermia (41-43 °C) did not affect normal cells while significantly inhibiting tumor 
cell growth [11]. In clinical applications, therapeutic hyperthermia ranges from 39-60 °C. 
Usually lower temperatures (39-43 °C) are used as an adjuvant treatment modality to 
radiotherapy or chemotherapy in whole-body and regional therapy. Higher temperature 
itself could be applied to kill deep seated tumors by focal lesions through laser or 
microwave produced hyperthermia. 
1.1 Intracellular Changes after Heat Application 
A variety of changes have been observed in cells after hyperthermia treatment including 
changes in cell membrane, metabolism, nuclear and cytoskeletal structures, 
macromolecular synthesis, expression of the heat shock genes and intracellular signal 
transduction [4]. However, it is generally believed that protein denaturing and cell 
membrane damage is the most direct effect of hyperthermia toxicity [3, 12, 13]. Protein 
starts to denature when the temperature is greater 40 °C, which leads to alterations in 
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multimolecular structures (e.g. cytoskeleton and membrane) and enzyme activity [14]. 
When the function of the enzyme complexes for DNA synthesis and repair is impaired, 
irreversible damage could occur.  
Nucleic acid damage is more likely to happen during the S phase of the cell cycle when 
the DNA is being synthesized. The newly synthesized DNA is vulnerable to heat stress. 
The double strand DNA might be joined incorrectly or contain aberrant base pairs under 
heat stress. At the same time, mutations can occur due to damaged DNA repair 
mechanisms under hyperthermia. Hyperthermia can also inhibit the DNA replication 
process itself through inactivation of some key enzymes [15]. Nucleic acid damage could 
also occur in the M phase of the cell cycle when chromosomes are dividing. As a result, 
cells die when they undergo mitosis. 
Cell membranes could be affected during hyperthermia, which is a key feature in thermal 
chemosensitization as altered membrane properties may facilitate drug uptake. Fluidity 
and permeability of the cell membrane may be modified upon heat exposure [16]. 
Generally, during hyperthermia permeability is increased especially to some small 
molecules. The efflux of proteins and enzymes from within the cell might trigger an 
immune response against tumor cells in vivo. If chemotherapy drug is applied together 
with hyperthermia, more drugs can accumulate at the tumor site due to the increased 
membrane permeability. 
Hyperthermia affects several key functions of the cytoskeleton. Cytoplasmic streaming 
processes can be halted. Heat stress can also lead to the depolymerization and 
inactivation of microtubule proteins, and fragmentation of the mitotic spindle, which will 
result in cytokinesis disruption. Actin filaments can become insoluble under heat stress 
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and loose their function with increased temperature [17-19]. Cells undergoing division 
are most vulnerable to hyperthermia related cytoskeletal damage leading to cell death. 
Since Nucleic acids and cytoskeleton damages are most likely to happen during mitosis, 
cancer cells are more susceptible to hyperthermia as cancer cells undergo much faster cell 
division events than normal cells do. 
1.2 Thermotolerance and Heat Shock Protein Expression 
Cancer cells may confer thermotolerance as a result of continuous heat exposure or after 
pre-hyperthermia treatment. Cells that have developed thermotolerance are less 
susceptible to heat induced cytotoxicity. The induction of thermotolerance seems to be 
temperature dependant. Moderate hyperthermia is more likely to induce thermotolerance, 
where 43°C seems to be a critical temperature [20]. After exposure to temperatures 
higher than that, cells undergo extensive protein denaturing and die passively (necrosis). 
After exposure to lower temperature hypertehrmia, thermotolerance develops rapidly  
after 8 – 10 hours [20]. In one report, it was found to be developed after 30 minutes under 
continuous 43 °C hyperthermia exposure [16]. Also thermotolerance can develop rapidly 
by cooling down to 37 °C between two heat shock treatments [16]. Thermotolerance is 
reversible if the cells are returned to normal temperature. However, thermotolerance 
decay takes much slower than its induction, usually in 3 to 5 days in most cells [21, 22]. 
The development of thermotolerance is mainly due to heat shock protein (HSP) 
expression [23]. HSP has been discovered in human as well as various other animals. In 
vitro cell culture experiments have demonstrated that hyperthermia below a certain 
temperature could induced HSP expression, which subsequently induces thermotolerance. 
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This has been confirmed by other means such as HSP transfection into cultured cells 
resulting in significant decrease of thermosensitivity [1]. 
HSP are molecular chaperones [24]. The function of chaperone is to correctly assembly 
other macromolecules such as proteins and nucleosomes. When proteins and 
nucleosomes are synthesized, chaperones attach to them and help them fold to correct 3D 
conformation and perform their normal biological function. Chaperones themselves are 
not components of these macromolecules. When folding is complete, they disassociate. 
Hyperthermia can severely affect protein folding. Under heat stress, newly formed 
protein polypeptide chains and subunits tend to aggregate and lose their biological 
function. Thus, HSP as a molecular chaperone, its overexpression is a normal cellular 
protective mechanism to encounter heat stress because they can repair misfolded proteins. 
HSP are classified by their molecular weight. To date, HSP are usually divided into 5 
groups: small HSP (MW<40 kDa), HSP60, HSP70, HSP90 and HSP100. Elevated HSP 
expression is not restricted to hyperthermia, other stresses such as infection or hypoxia 
could also trigger their upregulation. HSP are actively involved in the protection of cells 
against heat damage. They localize to the cytoskeleton and help reinforce structural 
proteins and enhance their tertiary configuration following treatment with heat [23, 25]. 
HSP also helps resist DNA fragmentation upon heating and decreases cell apoptosis [26].  
The expression of HSP is also temperature dependant. Moderate hyperthermia stimulates 
HSP synthesis. With further elevation of temperature to a distinct threshold, inhibition of 
HSP expression occurs. In general, it is widely accepted that HSP inhibits hyperthermic 
cell death, especially apoptosis [27-30]. 
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1.3 Hyperthermia Induced Apoptosis and Necrosis 
Generally, cells are committed to death through two distinct pathways: apoptosis and 
necrosis. Necrotic cell death is passive and involves lysis formation from the damaged 
cell and the release of its cellular content to the surrounding environment [31]. Necrosis 
is a traumatic cell death and occurs when the injury to the cell is acute. As a result, 
inflammatory response always follows.  
Apoptosis, in contrast, is an active and programmed cell death which involves 
condensation of nuclear chromatin, cytoplasmic shrinkage, membrane blebbing and 
externalization of phosphatidylserine, nuclear fragmentation and, finally, formation of 
apoptotic bodies [32]. Apoptosis plays an important role for cell death in development 
(e.g., apoptosis of the cells between the fingers lead to the differentiation of fingers and 
toes at embryo stage), maintaining homeostasis, and removing both the ineffective and 
immature cells of the body by the immune system. It could also be initiated by external 
stresses such as viral infection, DNA damage from excessive heat, radiation or toxic 
chemicals, which are routine strategies used by many cancer therapeutic agents. 
Apoptosis process malfunction is a major reason for cancer development as it permits the 
survival of cells after mutagenic DNA damage and uncontrolled growth. Studies have 
demonstrated that p53 gene is required for the efficient activation of apoptosis after 
irradiation or chemotherapy [33, 34]. Therefore, mutations on p53 can lead to increased 
resistance to chemotherapeutic agents on cancer cells [35]. 
Hyperthermia is capable of inducing both necrosis and apoptosis in vitro depending on 
the temperature [36]. In a malignant fibrous histiocytoma cell line, Yonezawa and 
coworkers proved that apoptosis could only be induced by heating up to 43 °C for 1 hour, 
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a temperature lower than that was not able to induce apoptosis no matter how long the 
exposure duration is [37]. They also observed that, with increased temperature (46°C for 
1 hour), necrotic cell death seems to be dominant where cells are seriously injured and 
die before the initiation of apoptosis.  
HSP expression is also involved in the transition from apoptosis to necrosis. HSP 
expression initiates with temperatures beyond 37 °C, they refold damaged intracellular 
proteins and helps resist DNA fragmentation thus protecting cells from stress injury. 
When the critical temperature for triggering apoptosis is reached (around 43 °C), the 
sustained thermal stress degenerates the regulation process. Nuclear chromatin 
condensates with HSP overexpression; meanwhile, the cytoplasma starts to shrink, and 
apoptotic tissue forms. If the temperature continues to increase, the critical temperature 
for triggering necrosis is reached (around 46 °C), the cellular proteins are denatured at 
that high temperature and the cell dies passively, which is necrotic cell death. 
The induction of apoptosis by hyperthermia in cancer cells is cell line dependant. The 
reason might be that cancer cells usually have an impaired apoptotic regulation system. 
The apoptotic pathway is missing in at least some types of cancer cells. Yonezawa and 
coworkers observed a direct transition to necrosis in osteosarcoma with increasing 
temperature [37].  Those cells survived in 43 °C but directly underwent necrosis when 
they increased the temperature to 44 °C. 
1.4 Thermal Dosimetry  
1.4.1 Thermal dose dependent cell death 
Treatment outcome of hyperthermia is highly thermal dose dependant. The temperature 
of the hyperthermia treatment and the exposure duration at that temperature could make a 
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great difference in tumor growth. After examining numerous survival curves of different 
cell lines upon heat treatment, the threshold temperature for thermal damage was found. 
This threshold temperature is also called a “breakpoint”. For example, Roizin-Towle [38] 
studied the cell death of Chinese hamster ovary (CHO) cells from 42-45 °C for up to 5 
hours. He observed that a 42 °C hyperthermia treatment for 5 hours showed very little 
cytotoxicity. However, after increasing the temperature to 42.5 °C, almost all cells were 
killed during the same period of heat exposure. Other research groups observed similar 
phenomena using different cell lines. Dewhirst et al. [39] concluded that once the 
hyperthermia treatment starts to show cytotoxicity, the rate of cell death, which is 
exponential with exposure time, is dependent on temperature. The change in the rate of 
cell killing below and beyond the breakpoint is generally believed to be related to the 
cells acquiring resistance to hyperthermia treatment during heating [39]. Heating above 
the breakpoint would not induce thermotolerance during the heating period; however 
cells could acquire thermotolerance after that heating period no matter whether the 
temperature is above or below the breakpoint. 
From the survival curve, researchers tried to build mathematical models to connect cell 
killing with the temperature of exposure and the duration of exposure. Some of the first 
attempts involved using Arrhenius analysis to study the cell survival curve mentioned 
above. The Arrhenius plot, which is produced by Arrhenius analysis to those curves, 
could be used to estimate the energy (heat) needed to inactivate the cells. Here, I will not 
go into the details of this analysis since it is not the focus of this study. Detailed 
procedure could be found in a number of publications [6, 38]. The Arrhenius plot is 
typically biphasic which also suggests the existence of a “breakpoint”. The plot is steeper 
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below the breakpoint than above it. The calculated inactivation energy is usually around 
120–150 kcal/mole, which is consistent with the heat energy required to inactivate 
proteins and enzymes [40].  
1.4.2 Cumulative equivalent minutes @43 °C model (CEM43) 
Although the Arrhenius analysis could be used to calculate the inactivation energy, it is 
hard to compare two different time-temperature combinations in the Arrhenius plot. 
Therefore, in order to normalize different treatment regimes (time-temperature 
combination) to a common unit, several methods have been developed.  
Sapareto and Dewey [41] proposed the term “thermal isoeffective dose” (meaning two 
different time-temperature combinations produced the same cell killing effect) for 
comparing different time-temperature combinations. This simple method is based on the 
fact that cell death under hyperthermia treatment is exponential; therefore, this 
relationship can be expressed mathematically by the following isoeffect equation: 
1 2( )
1 2 *
T Tt t R  , (Equation 1) 
where T1 & T2 are two different treatment temperatures and t1 & t2 are the duration of 
treatment at temperature T1 & T2 respectively. R is an empirical value which defines the 
shape of the dose-response curve. Usually, R is termed as a compensation constant and is 
assumed to be 0.5 above 43 °C and 0.25 below 43 °C by Sapareto and Dewey [41]. It has 
been shown in a number of rodent and human cell lines that cytotoxicity start to occur 
around 43 °C after continuous heat exposure; therefore, it was considered as the 
breakpoint temperature in this model [39]. Sapareto and Dewey [41] also found out that, 
when the temperature is above 43°C, with each 1 °C increase, the time needed to produce 
the same cell killing effect is cut in half; while below 43 °C, with each 1 °C temperature 
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drop, treatment time has to be extended by 4 times to compensate for that 1 °C difference. 
Therefore, for any hyperthermia treatment, its thermal dose can be described as the 
cumulative equivalent minutes at 43°C.  From equation (1), if we set T1 = 43 °C and 
allow T2 to be vary during heat treatment, we get  
(43 ( ))
43
T tCEM R dt  , (Equation 2) 
which is the widely used cumulative equivalent minutes @43 °C model. 
2. Hyperthermia as an Adjuvant Treatment Modality to Chemotherapy or 
Radiotherapy 
The efficacy of current hyperthermia treatment modalities alone is not sufficient enough 
to substitute for already established methods such as chemotherapy or radiation therapy, 
but, they could be applied adjuvant to those modalities to enhance the cancer cell 
killing/growth inhibition effect. More recent researches have been focusing on 
magnifying the synergistic effects of combining hyperthermia and chemotherapy or 
radiotherapy in order to achieve better therapeutic effects [42]. Thermal 
chemosensitization and thermal radiosensitization effects have been observed both in vivo 
and in in vitro cell culture experiments [1].  
Clinically, several phase-III studies have been carried out to study the effect of the 
hyperthermia radiotherapy combinational treatment modality. Patients within the 
combinational treatment group achieved better response rate and survival rate over the 
radiotherapy alone group. Compared to hyperthermia radiotherapy, there are many trials 
to date regarding the application of hyperthermia as an adjuvant to chemotherapy. Most 
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of the reports were focusing on the effect of hyperthermia-chemoperfusion following 
surgery compared to surgery alone [43-46]. 
2.1 Chemotherapy in Cancer Treatment and Multidrug Resistant 
In cancer treatment, chemotherapy involves using any type of chemicals to kill cancer 
cell. Most chemotherapy agents target at fast dividing cells and impair cell mitosis. Since 
cancer cells divide much faster than most normal cells, they are more sensitive to 
chemotherapy agents because cell division events are more likely to happen at any time. 
The downside of this cancer targeting strategy is that other healthy fast dividing cells can 
also be affected, such as those functioning in hair growth and those responsible for the 
replacement of the intestinal epithelium.  
Cancer cells can become resistant to chemicals over time. Research has shown that if an 
anticancer drug (e.g. doxorubicin (DOX)) can not kill the entire tumor when they are first 
introduced, then the survived cancer cells can become insensitive to not only DOX but 
also a variety of other chemotherapy agents. This effect is called multidrug resistant 
(MDR). The therapeutic effect of chemotherapy is greatly hindered by multidrug resistant, 
which is the major cause of treatment failure in metastatic cancers. Cancer cells which 
respond initially can acquire resistant by spontaneous mutation or DNA transfer to 
acquire multidrug resistant [47].  
Cancer cells achieve multidrug resistant by altered membrane transporter activity, which 
is mediated by an energy dependent drug efflux pump. A decreased net cellular 
accumulation of the chemotherapy agent is always observed in MDR cells. Research has 
shown that a plasma membrane P-glycoprotein (P-gp), which belongs to a large ATP-
binding cassette protein family with a molecular weight of 170,000, is consistently found 
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to be over-expressed in a variety of multidrug-resistant cell lines [48]. To date, P-gp 
overexpression is still the best-understood mechanism of MDR. Cancer cells achieve 
drug resistant by P-gp actively exporting many functionally and structurally unrelated 
hydrophobic anticancer drugs using the energy of ATP hydrolysis [49]. Therefore, P-
glycoprotein is believed to be the primary mediator in multidrug resistance.  
2.2 Hyperthermia-Chemotherapy Interaction 
Various Pre-clinical reports have suggested the role of hyperthermia in overcoming P-gp 
regulated MDR. Using ultrasound induced moderate hyperthermia (20 min @41°C), Liu 
and his research group [49] observed a 2-6 fold increase in DOX uptake in MDR cells 
compared to control cells. In Moriyama-Gonda’s data [50], membrane permeability as 
well as reduced P-gp expression was achieved by 44 °C heating for 60 min. The exact 
mechanism of hyperthermia overcoming MDR is still under investigation. Some research 
groups consider the mechanism exemplary, which means its causes are multifactorial: 
transmembrane conductivity, sodium/potassium-ATPase activity, and glutathione 
metabolism could all be affected [1]. Whereas in other observations, only increased drug 
uptake was found due to enhanced membrane permeability under hyperthermia [49]. 
On the other hand, MDR has been observed to be associated with the occurrence of 
thermotolerance induced by hyperthermia. It is not clear whether there is a causation 
relationship between MDR and thermotolearnce, however, the simultaneous induction of 
MDR and thermotolerance under hyperthermia has been reported extensively in various 
trials [23, 30, 51-53]. Again, it seems that the induction and overcoming of MDR using 
hyperthermia is temperature dependant. Below a critical temperature (around 42°C), 
hyperthermia is more likely to induce MDR and thermotolerance (through HSP 
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expression). Beyond that temperature, hyperthermia has shown great potential in 
inducing thermal chemosensitization and overcoming MDR which may result in the 
accumulation of chemotherapy agents within the target cells [1].  
3. Overview of the Specific Intracellular Events Following Hyperthermia 
Supporting the Hypothesis for This Study 
So far, the cancer cell killing/growth inhibition capability of hyperthermia has been 
established both by itself and as an adjuvant treatment modality. However, its exact 
mechanism of action is still not very clear. The only thing that is widely accepted is that 
the temperature and the duration of the heat treatment play a very important role. The 
specific cellular events following hyperthermia, such as HSP expression, 
development/reversal of thermotolerance and MDR, hyperthermia-chemotherapy 
interaction, apoptosis/necrosis cell death, are all temperature dependant.  
Figure 1 gives a schematic roadmap of the intracellular events following hyperthermia 
(with increasing temperature). Unfortunately, since each research group has their own 
specific interest and experimental setup (e.g. different cell lines, hyperthermia delivery), 
it is hard to compare the results between different research groups. Therefore, the 
diagram is an approximation and may be incomplete since there are other parameters that 
can influence the effect of hyperthermia, such as the rate of heating which are not 
included in this diagram. The reason is that reports regarding the influence of heating rate 
are very rare. This dissertation attempts to address the influence of heating rate.  
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Figure 1 Hypothesized time course of intracellular events following hyperthermia based on 
current literature. 
Practically, temperatures ranging from 41-47 °C are usually used for inducing 
hyperthermia. Hyperthermia lower than 41 °C may have adverse effects as cells can 
protect themselves through cellular HSP expression in that temperature range. Moreover, 
mild hyperthermia may help cells develop MDR. Temperatures higher than 47 °C could 
effectively induce necrosis in almost any type of cells through protein denaturing; 
however, those temperatures are hard to apply in practice, as healthy tissue will also be 
affected. Thus, hyperthermia treatment to tumor tissue at around 43 °C seems to be 
optimal for achieving a successful final treatment outcome; this temperature is easier to 
reach clinically compared to 47 °C so it could reverse MDR and initiate apoptotic cell 
death.  
Another issue that needs to be pointed out is the initiation of these intracellular events 
(HSP overexpression, induction/reversal of MDR, apoptotic cell death, etc.) requires 
extended exposure, usually in tens of minutes at least. Therefore, it is reasonable to 
hypothesize that the rate of temperature increase will affect the development of HSP 
expression, induction/reversal of MDR, and apoptotic cell death. A rapid rate of 
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hyperthermia to 43 °C can circumvent extensive HSP expression and induce 
thermal chemosensitization thus killing cancer cells synergistically. 
4. Current Hyperthermia Delivery Methods: Pros and Cons 
4.1 The Treatment of Cancer by Hyperthermia – Rationale 
From in vivo experiments, it has been observed that normal tissue and tumor tissue 
behave differently during hyperthermia treatment. This difference is because of the 
characteristic difference between normal and tumor tissue physiology but not the 
hyperthermia sensitivity of normal and tumor cells [2]. Compared to normal tissue, tumor 
vascular architecture is usually more chaotic. As a result, hypoxia and low pH (2-4) is 
usually found in tumor tissues, which makes tumor cells more sensitive to hyperthermia 
than normal cells [2]. Most normal tissues, except for in the nervous system, can maintain 
their function under up to 44 °C hyperthermia within 1 hour [54]. Irreversible damage in 
the central nervous system was observed after 40-60 min hyperthermia at a temperature 
of 42-42.5 °C [55]. The peripheral nervous system appears to be more resistant to heat 
stress than the central nervous system; Wondergem et al [56] reported a full recovery 
within four weeks from temporary functional loss of the peripheral nervous system after a 
44 °C hyperthermia treatment for longer than 30 minutes.   
4.2 Types of Hyperthermia  
In clinical applications, hyperthermia can be divided into three types: local, regional and 
whole-body hyperthermia. 
4.2.1 Local hyperthermia 
Local hyperthermia is usually applied to a tumor while the surrounding normal tissue is 
not heated.  Local hyperthermia treatment is a well-established cancer treatment modality 
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with a basic principle, that is, if a 42 ºC hyperthermia can be maintained in a tumor for 
one hour, the tumor cells will be destroyed [57]. Local hyperthermia can be applied by 
external or interstitial methods. 
External local hyperthermia: External local hyperthermia is usually performed with 
superficial applicators, such as RF, microwave or ultrasound. Although the penetration 
depth can be tuned by the size or the frequency of the applicator, the therapeutic depth of 
this type of hyperthermia is usually no more than 3-4 cm [57]. In regions with an 
irregular surface (head, neck, etc.), the treatment depth is further limited.  
Intraluminal local hyperthermia: Intraluminal or endocavitary methods can be used to 
treat tumors within or near body cavities. These cavities include gastrointestinal 
(esophagus, rectum), gynecological (vagina, cervix, and uterus), genitourinary (prostate, 
bladder), and pulmonary (trachea, bronchus) [58]. During the procedure, endocavitary 
antennas will be inserted into these lumens for delivering heat.  
Interstitial local hyperthermia: In order to treat deep seated tumors where external local 
hyperthermia is unreachable, such as brain tumors, interstitial local hyperthermia can be 
applied [59]. There are several types of applicators for delivering energy interstitially, 
including local current field techniques utilizing RF energy at a frequency of 0.5 MHz; 
small microwave antennas delivered by hollow tubing at 300-2450 MHz; ferromagnetic 
seed implants, hot water tubes and laser fibers [57]. However, due to its invasive nature, 
it is difficult to perform this procedure repeatedly, also, the applicable sites are limited.  
4.2.2 Regional hyperthermia   
When a tumor is locally advanced or deep seated, such as those in the abdomen or pelvis, 
regional hyperthermia can be used. Unlike local hyperthermia, in regional hyperthermia it 
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is hard to avoid a temperature increase in normal tissues; therefore, it requires that heat 
dissipation in normal tissue is faster than in the tumor, usually due to blood flow. Most 
clinical trials have used regional hyperthermia as an adjuvant to chemotherapy or 
radiotherapy, mostly in the pelvis when locally advanced or recurrent tumors are present, 
including rectal carcinoma, cervical carcinoma, bladder carcinoma, prostate carcinoma or 
soft tissue sarcoma. 
Deep regional hyperthermia by external applicators: Treatments of deep seated tumors 
are difficult with electro-magnetic (EM) energy since it can be absorbed by human tissue 
very quickly [60]. Therefore, in order to deliver energy to the tumor while avoiding 
overheating adjacent normal tissue, applicator arrays are usually used [61]. Typical 
systems include the Sigma-60 and Sigma-Eye.   
Regional perfusion hyperthermia: Regional perfusion is a technique where heated fluids 
(usually carrying chemotherapeutic agents) are used to perfuse cancerous tissue. It is 
usually used to treat cancers in the arms and legs like melanoma or soft tissue sarcoma, 
where the cancer is in advanced stage and nonresectable. When regional hyperthermia is 
applied to limbs and without a cytotoxic agent, the temperature can be increased to 
around 43 °C for as long as 2 hours [2]. However, if a cytotoxic drug is applied 
simultaneously, the temperature must be lower to avoid unacceptable toxicities. It can 
also be applied in an organ such as the liver and lung, or in a body cavity, such as the 
peritoneal cavity, where the temperature can reach 41-42 °C with heated anticancer drug 
[57]. Clinically, regional perfusion hyperthermia combined with chemotherapy has 
shown much higher response rate than treating the caner with systemic chemotherapy. 
However, compared to externally applied hyperthermia, the procedure is more risky. 
 17
Adverse effects can be more sever and persistent, such as neuropathy which can lead to 
amputation of limbs in the worst cases.   
4.2.3 Whole body hyperthermia (WBH) 
WBH has been investigated since he 1970s as an adjuvant modality to chemotherapy or 
radiotherapy [62], where metastatic cancer has spread throughout the body. The 
temperature of WBH is usually limited to 42 °C because temperature higher than that can 
cause irreversible damage to brain and liver tissue. But this temperature can be 
maintained for several hours.  
The application of WBH can be divided into three major types: thermal conduction, 
extracorporeal induction and radiant or EM induction [57]. Thermal conduction can be 
achieved by immersion in heated fluids [63], heated air [57], heated blanket [64] or using 
thermal chambers (similar to incubator). In extracorporeal induction, blood is first 
pumped out of the patient’s body, heated to 42 °C, and then put back into the body [65].  
Since the whole body temperature will be elevated, WBH can be applied only to patients 
in a good health condition, otherwise, significant adverse effects may occur given that the 
basal metabolic rate of a patient will be doubled at 42 °C compared to 37 °C [66].  
4.3. Hyperthermia Heating Systems 
Recently, localized hyperthermia has been achieved by external energy sources. 
Especially diathermic heating devices have became a new research focus in the treatment 
of cancer due to their targeting capability, which eventually leads to accurate 
hyperthermia delivery to the tumor and small side effects to the healthy tissues [16]. Most 
clinically used hyperthermia systems are diathermic, which means the heating of body 
tissues due to their resistance to the passage of high-frequency electromagnetic radiation, 
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electric current or ultrasonic waves. These systems can be interfaced with magnetic 
resonance image (MRI) systems for noninvasive monitoring of tumor temperature. With 
the advance in nanotechnology, nanotechnology-based sources have become a new 
research focus [67].  
4.3.1 Ultrasound 
The ultrasound induced hyperthermia effect is caused by tissue absorption of ultrasound 
waves at the frequency of 2-20 MHz. Theoretically, ultrasound has the best combination 
of short wavelengths among all diathermic devices and therefore has low attenuation 
coefficient, which allows for deep penetration the in human body with the ability to focus 
power into small regions [57]. With the technique advance, newly designed ultrasound 
hyperthermia delivery systems equipped with multiple applicators have achieved 
improved heating uniformity and controlled depth of penetration [68, 69]. However, in 
application, the use of ultrasound is limited by the fact that it is incapable of penetrating 
air and bone. 
4.3.2 EM fields 
EM field can cause temperature increase in biological tissues. According to the frequency, 
EM field can be in the radiofrequency (RF) or microwave range. Frequency between 300 
MHz and 300 GHz are assigned to microwave. The most commonly used frequencies for 
microwave hyperthermia are 433, 915, and 2450 MHz [58]. Frequencies higher than 
2450 MHz have no practical value due to their limited penetrations. RF by definition 
occupies the band between 3 kHz and 300 GHz. In hyperthermia application, it generally 
means frequencies below microwave range, usually between 10-120 MHz [57]. The RF 
frequencies of 13.56 and 27.12 MHz have been widely used in hyperthermia [58]. 
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4.3.3 Radiofrequency  
Exposure of living organisms to radio frequency electromagnetic radiations (RF-EMFs) 
produces heat within tissues primarily from molecular rotation [70]. There are three 
major types of RF hyperthermia, according to the mode of generating RF field. 
Resistive: Resistive heating is achieved by an EM field produced by alternating RF 
currents through needle or plate electrodes. The operating frequency should be higher 
than 100 kHz to prevent excitation of nerve action potentials. 
Capacitive: Capacitive heating operates by putting patients inside a capacitor. More 
specifically, by displacement currents generated between two capacitor plates. It is 
simple to apply, but a major problem associated with it is that the subcutaneous fat tissue 
is often overheated.   
Inductive: Inductive heating is achieved by a time varying magnetic field passing 
through the body and generating eddy currents which subsequently produces Joule’s heat. 
The magnetic field is usually generated by solenoidal loops. Since the induced electric 
fields are parallel to the tissue interface, heating is maximized in muscle rather than in fat 
and therefore can penetrate tissues > 5 cm. The disadvantage with inductive heating is 
that the temperature distribution is not homogenous [71]. The pattern is usually toroidal 
shape with very small temperature elevation at the center. 
4.3.4 Microwave 
When treating patients with an EM device within the microwave frequency range, energy 
is coupled into tissues through waveguides, dipoles, or other radiating devices [57]. Due 
to its high frequency, a microwave hyperthermia device is capable of directing and 
focusing the energy into tissues by direct radiation from a small applicator [72]. However, 
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also due to its high frequency, its penetration depth is shallow compared to RF; besides, 
most microwave equipment requires cooling (usually water) of the device-patient 
interface. 
Early diathermic devices use a single applicator which is unable to steer or focus energy. 
Therefore, single applicator devices can only treat relatively small superficial tumors. In 
order to apply heat into deep seated tumors without overheating skin or superficial 
normal tissue, multichannel coherent phased-array systems have been developed. An 
array of applicators with variations in phase, frequency, amplitude, and orientation can 
theoretically deliver heat more precisely with deeper penetration compared to a single 
applicator.  
The major problem with diathermic heating is to achieve an elevated temperature in the 
cancerous tissue, meanwhile, avoid excessive heating of the surrounding healthy tissue in 
the presence of electrical inhomogeneitites. This problem could be solved by 
nanotechnology based sources. 
4.4 Nanotechnology Based Sources  
One major obstacle that prevents hyperthermia from achieving therapeutic effect is the 
lack of direct targeting techniques. Superficial malignances could be treated with 
hyperthermia effectively; however, other treatment modalities are also superior in 
treating exposed malignances.  Deep body tumors are hard to reach by noninvasive 
external energy sources, where direct heating methods like whole body hyperthermia 
aiming to deliver hyperthermia from outside the body to the tumor will inevitably cause 
damage to healthy tissue before the deep tumor region temperature can reach the 
therapeutic temperature. This problem could be solved by invasive methods such as 
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regional perfusion or interstitial hyperthermia through probes; the disadvantage, of course, 
is that those methods are invasive and require complex procedures.  
The currently available modalities of hyperthermia are often limited by their inability to 
selectively target tumor tissue and therefore carry the risk of collateral organ damage. 
Nanotechnology-based thermal therapy is a special form of interstitial hyperthermia 
which can selectively delivery heat to the tumor by depositing energy-absorbing agents 
within tumor tissues to facilitate localized heating. The localization of nanoparticle into 
the tumor tissue can be achieved by passive targeting of nanoparticles due to the leaky 
vasculature of tumor, or by active targeting through tagging it with appropriate ligands 
that selectively interact with tumor cell membrane receptors. To date, many nanoscale 
agents have been tested with different activation techniques.  
4.4.1 Near-infrared (NIR) photothermal therapy with nanoparticles  
Agents that absorb within the near infrared (NIR) region can be an ideal candidate for 
delivering hyperthermia. Light activation of dyes result in heat production. Normal tissue 
absorption of light is minimal within the NIR region, between 700 nm and 900 nm, which 
is above the hemoglobin absorption band and below water absorption peak, the two major 
light absorbers of light in the human body. Therefore, compared to other wavelengths, 
NIR light can penetrate deeper with little energy loss. Under certain thresholds of 
irradiation, tissue will not sustain irreversible damage [73]. Currently, gold nanospheres, 
gold nanorods, gold nanoshells, gold nanocages, and carbon nanotubes are the chief 
nanostructures that have been demonstrated in photothermal therapy due to their strongly 
enhanced absorption in the visible and NIR regions [74]. Of these, the first three 
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nanostructures are studied extensively because of their ease of preparation, ready multi-
functionalization, and tunable optical properties.  
Carbon nanotube: The mechanism of carbon nanotube producing heat involves 
excitation of optical transitions with relaxation resulting in enhanced vibrational modes in 
the carbon lattice that cause solution heating. Various in vitro and in vivo studies have 
been conducted to test their photothermal effect on cancer therapy. For most in vitro 
studies, a typical system includes a laser emitting around 800 nm, with a power flux of 1-
3 W/cm2. The treatment time is usually 3 minutes. The concentration of the nanotubes 
used is around 2.5-5 mg/L [75-77]. Recently, more and more in vivo trials have been 
reported. In a study conducted by Moon et al [78], single walled carbon nanotubes 
(SWCNs) were coated with PEG to increase their retention time in the circulation. Using 
an 808 nm laser with an output at 5.3 W, they managed to eliminate a 70 mm3 tumor by 3 
minutes laser exposure in mice. The concentration they used was 120 mg/L, which is 
much higher than the in vitro cases reported. Burke et al [79] examined the long term 
survival of mice treated with multi-walled carbon nanotubes (MWCNs) after NIR 
radiation, however, even higher concentration (1000 mg/L) has to be used to achieve 
complete tumor recession.  
Gold (Au) nanoparticles: Another important candidate for NIR photothermal therapy is 
Au nanoparticles, including Au nanoshells, nanoclusters and nanorods. Research has 
shown that the interaction of Au nanoparticles with excitation light corresponding to their 
surface plasmon resonance (SPR) could generate heat [80]. Therefore, by tuning the SPR 
of Au nanoparticles, which is controlled by the aspect ratio of the nanoparticle [74], Au 
nanoparticels with different absorption peak could be synthesized easily. Phase I human 
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clinical trials are ongoing to test their clinical potential [12]. Au nanoparticles can be 
much stronger NIR absorbers than conventional NIR dyes and therefore a more effective 
photothermal coupling agent. For example, the calculated absorption cross sections of Au 
nanoshell are 6 orders of magnitude of indocyanine green (ICG) [81, 82].  
In a mouse model, O’Neal et al [81] treated tumors with Au nanoshell by tail vein 
injection and achieved complete tumor regression. The 808 nm NIR illumination was 
applied with an 800 mW laser for 3 minutes at 4 W/cm2. In the tumor region, the 
recorded temperature was around 50 °C after 30 seconds laser exposure [81]. In an early 
study conducted by Hirsch et al [82], PEG coated Au nanoshells were injected 
interstitially into the tumor region and excited with a 800 mW laser emitting at 820 nm. 
The power density was also 4 W/cm2 and the treatment time was less than 6 minutes [82]. 
Both studies showed that laser application to nearby healthy tissue or to tumor without 
nanoshell treatment did not induce a significant temperature increase probably because of 
the preferential accumulation of the Au nanoshells into the tumor region which 
minimized the damage to surrounding tissues.  
In a more recent study, Li et al [83] compared passive targeting and active targeting in a 
mouse tumor model. They used arginine-glycine-aspartic acid (RGD) conjugated 
dendrimer-modified gold nanorods (RGD-dGNRs), where RGD is used to achieve tumor 
targeting, dendrimer coating was used to conjugate RGD with Au nanorods. In their 
study, the NIR laser was emitting at 808 nm at a power density of 24 W/cm2 and a spot 
size of 5 mm diameter. Therefore, the calculated power output of the laser was around 4.7 
W. The treatment time was 5 minutes. When the tumors reached 5 mm in diameter, they 
were irradiated four times per month, once every week. Prior to NIR irradiation, mice 
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were injected with either 200 µg of RGD-dGNRs to study active targeting or 200 µg of 
dGNRs to study passive targeting. Their results showed a much higher tumor growth 
inhibition capability of RGD-dGNRs than pure dGNRs 28 days post treatment.  
The biodistribution of Au nanoshell studies have been carried out by several research 
groups using tumor bearing mice [83, 84]. Results showed that PEG coated Au nanoshell 
were mainly concentrated in the spleen, liver, and tumor.  
Dye encapsulated nanoparticles: Encapsulating NIR dye into a nanoparticle can increase 
its availability at the tumor site as well as decrease its presence in the healthy tissue. In 
our lab, indocynine green (ICG) encapsulated within PLGA nanoparticle at a 
concentration of 5.5 mg/L (~7µM ICG) has been shown capable of producing a 43 ºC 
hyperthermia within 3 min of laser exposure at a power density of 1 W/cm2. 
4.4.2 Nanoparticles excited with RF field 
Carbon nanotubes and Au nanoparticles can also be excited by RF field. Recently, some 
research groups have explored the possibility of using the conductivity properties of gold 
nanoparticles (GNPs) and single-walled carbon nanotubes (SWNTs) to potentiate heating 
efficiency of an RF field. Traditional RF field induced hyperthermia is usually invasive 
and can cause collateral organ overheating. GNPs and SWNTs can be absorbers of RF 
energy and thus can improve heating specificity and produce noninvasive heating.  
The heating capacity of GNPs is determined by the concentration of the GNPs and the 
power of the RF field [85, 86]. From Gannon’s study [85], the rate of heating increased 
with increasing concentration of GNPs. Using a 200 W RF field working at 13.56 MHz, 
their data showed that 67 µM GNPs can raise the temperature to 90 °C (from a baseline 
of around 25 °C) after 5 minutes whereas 1.1 µM barely had any heating effect. If the 
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power is increased to 800 W, 67 µM GNPs can raise the temperature to 90°C within 90 
seconds. Cardinal et al. [86] exposed tumor-bearing rats to a RF field following the 
injection of GNPs and achieved total tumor ablation. In their study, they used a 35 W RF 
field generator working at 13.56 MHz. However, in the control groups which were 
injected with water, 4 °C temperature increase was recorded after applying the RF for 7 
minutes, but they claimed that thermal injury was not seen in control samples. 
SWNTs can also be excited by an RF field due to their resistive conductivity [87]. 
Similar to gold nanoparticles, the rate of heating is dependent on the concentration of the 
SWNTs and the power of the RF field. Gannon et al. [87] treated tumor-bearing rabbits 
with RF field following intratumor injection of SWNTs and achieved complete thermal 
tumor necrosis.  
When comparing GNPs with SWNTs, GNPS exhibit a higher heat production capacity. 
From Gannon’s data, using 600 W RF field, 67 µM GNPs (11.19 mg/L) was able to 
increase the temperature 80 °C (from 25 °C) within 2 minutes of exposure, whereas 250 
mg/L SWNTs can only increase temperature by 33°C within 5 minutes exposure [85, 87].   
4.4.3 Magnetic fluid hyperthermia (MFH) by magnetic nanoparticles 
Magnetic fields can induce heat when a local inductive material is implanted into the 
body. The problem with this type of heating is that overheating of superficial normal 
tissue could occur due to the occurrence of eddy currents near the surface of the human 
body. For this reason, eddy-current absorbers have to be applied during the application of 
magnetic field [57]. The absorbers are usually made of silicon rubber encapsulated with 
carbon powder.  
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Magnetic nanoparticles can be used to replace the local inductive implant to achieve 
more precise and noninvasive heating, which is called magnetic fluid hyperthermia 
(MFH). The magnetic nanoparticles are delivered to a tumor either intravenously or 
through direct injection. The heating mechanism of MFH is due to the rotation of the 
magnetic moment within a nanoparticle or of the entire nanoparticle within its 
surroundings [88, 89]. This magnetic moment of a particle changes orientation to align 
with the magnetic field. As the particle moment returns to its equilibrium position, the 
magnetic energy dissipates as thermal energy [88]. Meanwhile, the movement of particles 
in low-viscosity fluids causes frictional losses of their energy, which is released as heat. 
Currently the most commonly used particle formulation in MFH is iron oxide particles. 
They demonstrated no adverse effects on tissue when delivered into the lymph nodes of 
dogs [12]. Furthermore, it presents a high Curie temperature (minimum temperature at 
which the particle becomes paramagnetic) and high saturation magnetic moment [57].   
The problem with MFH is that the thermal enhancement capability of iron oxide is low, 
which leads to a high quantity of iron particles required to induce heating; tumors were 
injected with up to 10% total weight of iron oxide [82, 90].   
4.4.4 Advantages and disadvantages of different nanoparticle-based hyperthermia 
As has been discussed before, there are three major types of nanoparticle-based 
hyperthermia, NIR photothermal therapy, nanoparticle enhanced RF field hyperthermia, 
and MFH. 
For MFH, the advantage is that if low Curie temperature nanoparticles can be synthesized, 
the temperature of hyperthermia can be controlled fairly easily as the particles will stop 
responding to the magnetic field and thus stop producing heat when the Curie 
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temperature is reached. However, the disadvantage of MFH is also obvious. First of all, 
the application of a magnetic field would cause overheating of superficial normal tissue. 
Secondly, the heating capacity of iron particles is low which means a high quantity of 
particles is needed.  
Nanoparticle enhanced RF field hyperthermia could be a promising strategy for 
hyperthermia delivery. Compared to traditional RF field hyperthermia, it is noninvasive 
and more targetable. Furthermore, RF energy has been shown to penetrate tissue more 
deeply than NIR light. At 220 MHz, RF can penetrate 7 cm and this number increases to 
17 cm when the frequency is 85 MHz [12], whereas NIR light only penetrates ~1 cm into 
the tissue. The disadvantage of RF field is that it can cause temperature increase in 
healthy tissues. In one report [86], a 4 ºC increase was observed in tumor injected with 
water. Although no thermal damage was observed, this slight temperature increase could 
cause HSP overexpression and subsequently compromise the treatment outcome. 
When comparing GNPs and SWNTs in the application of RF field hyperthermia, GNPs 
might be a better choice since GNPs are better conductors of RF energy than SWNTs and 
fewer GNPs are need to achieve a target temperature. 
NIR photothermal therapy has shown the highest safety among all the three types of 
hyperthermia. When no absorber is present, the application of NIR laser would cause 
little if any temperature increase in the tissue because the tissue absorbs little light in the 
NIR and because the power of the laser used in this type of treatment is low (usually 
around 1-3 W, whereas power of the RF field is at least 100 W).   
When comparing organic and non-organic absorbers, non-organic absorbers, such as Au 
nanoparticles, carbon nanorubes, usually have a higher heating capability. But the issue 
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with those non-organic absorbers is their biocompatibility. Whether they are accumulated 
or removed from the body after finishing their role as heat inducers is not clear. In Li’s 
report [83], gold nanoparticles were still present 28 days after injection. With 
biodegradable organic absorbers, this issue would not exist. They will be cleared fairly 
quickly, usually in days. Another advantage with the organic dyes is that they can be 
more easily encapsulated, or incorporated into nano-scale drug carriers such as polymers 
or liposome and therefore can be more easily combined with drugs or imaging tracers. 
5. Hyperthermia-Chemotherapy Combinational Treatment Modality Used in This 
Study 
The application of heat by itself as a cancer treatment modality has not yielded general 
success and its efficacy is still controversial. Compared to radiation which induces direct 
cellular DNA damage via breaking DNA double-strand, heat is not able to cause severe 
DNA-damage by itself. Compared to chemotherapy which mostly target fast dividing 
cells, hyperthermia lacks a specific feature which makes it targetable. This situation leads 
to a dilemma in hyperthermia application: on the one hand, extreme temperature (>47°C) 
is preferred in order to achieve ideal cancer cell killing and avoid adverse effect (HSP 
expression, MDR induction, etc) while on the other hand, extreme temperature will 
inevitably induce healthy tissue injury due to the lack of targeting capability. Therefore, 
in most clinical settings, lethal hyperthermia (>47°C) is rarely used although it is superior 
in inducing tumor necrosis; instead, hyperthermia is often used at sub-lethal level (<43°C) 
as an adjuvant treatment modality to magnify the therapeutic effect of radiation or 
chemotherapy. For this purpose, an ideal hyperthermia should be: 1) targetable; 2) 
able to avoid adverse effect such as HSP overexpression when delivered at sub-lethal 
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temperature; 3) able to achieve thermo-chemo sensitization when combined with 
chemotherapy (synergistic effect), especially when treating MDR cancer cells.  
In this study, a synergistic effect means hyperthermia aided the functionality of the 
chemotherapy drug, which could happen through facilitated drug uptake in cancer cells 
due to increased cell membrane permeability under hyperthermia conditions, or through 
inhibition of MDR thus allowing the drug to have a greater impact in MDR positive cells. 
The interaction between hyperthermia and chemotherapy could also be “additive” or 
“sub-additive”. An additive effect occurs when hyperthermia and chemotherapy act on 
the cancer cells on their own and do not affect each other; if the addition of hyperthermia 
compromises the effect of chemotherapy, the resulting total effect will be considered 
“subadditive”. An additive effect is calculated by summation of the cytotoxicity of each 
individual cancer treatment. Therefore, a synergistic effect can be determined by 
comparing the cytotoxicity of the actual combinational treatment to the calculated 
additive effect. If the cytotoxicity from the combinational treatment group is greater than 
the calculated additive effect, the combinational effect is defined as “synergistic”.  
In this work, a novel dye enhanced hyperthermia cancer treatment modality with future 
targeting capability was studied. This new approach employs a rapid temperature increase 
of localized heating to the cancer cell. The concept of combining chemotherapy and 
hyperthermia for treating cancer is not new. Many research groups have investigated the 
effect of hyperthermia on different cancer cell lines with and without chemotherapy. 
However, most of them employed an external heating apparatus which heats up cells 
gradually; none of them investigate the effect of rapid heat accumulation to the cancer 
cell. In this respect, this research is novel and therefore, it is important to first test 
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the cancer cell killing/growth inhibition effect of rapid rate localized heating in vitro 
and understand its mode of action.   
This new treatment approach was comprised of an ICG-NIR laser hyperthermia delivery 
system and a chemotherapy drug, DOX. NIR laser is chosen because of its tissue 
penetration property and its safety.  
5.1 DOX as the Chemotherapy Agent 
DOX was chosen as the chemotherapy agent in this combinational approach and was 
added with ICG simultaneously to a MDR positive cancer cell to study hyperthermia-
chemotherapy interaction through laser excited ICG.  
DOX is one of the most widely used chemotherapy agent in cancer treatment [91]. It is an 
anthracycline antibiotic that has the ability to stabilize DNA - topoisomerase II complex 
thus leading to the breakdown of DNA double strand and trigger p53-mediated apoptosis 
[92, 93]. Pegylated Liposomal DOX is recommended by the National Institute of Clinical 
Excellence, as the drug of choice for many patients with advanced ovarian cancer for 
whom first line chemotherapy has failed [94]. 
5.2 NIR Laser-ICG Hyperthermia Delivery System 
In this study, ICG was used as the heating agent. It absorbs laser energy in the near 
infrared range and converts the energy to heat. ICG is a dye with a tricarbon structure. Its 
absorption peak is about 800 nm. Upon exposure, ICG absorbs NIR energy and emits 
fluorescence light as well as heat upon returning to the ground state. The whole process 
takes place almost instantaneously. The final temperature that can be reached and the 
time it takes to reach that temperature depend on the power density of the laser and the 
concentration of ICG.  
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ICG has been approved by the FDA since 1956 for various clinical uses such as 
determining cardiac output and blood plasma volume, hepatic function assessment, 
capillary patency measurement, and localization of tumors in tissues [95, 96]. The 
application of ICG as a hyperthermia agent has not been reported extensively. Some use 
it to achieve high temperatures (beyond 60°C) for tissue welding. For example, Joie and 
coworkers used ICG as a hyperthermal agent in sutureless laser tissue welding, where 
pieces of tissue are fused using NIR irradiation [97]. 
So far, there are few reports in using ICG as a hyperthermia agent for cancer treatment. 
Most researches are focusing on its photodynamic effect [98, 99] which involves the 
generation of reactive oxygen free radicals (mostly singlet oxygen) to kill cancer cell by 
photooxidation. ICG is capable of producing both a photodynamic and photothermal 
effect using a NIR laser, depending on the laser’s power density. Usually, a low power 
density laser (< 0.1 W/cm2) [98] and a high concentration of ICG (>50 µM) were used to 
induce a photodynamic effect. In comparison, in photothermal applications, a higher 
energy laser is used (up to 20 W/cm2) [98] with a lower concentration of ICG, depending 
on the target temperature (usually <10 µM).  
II. STATEMENT OF PURPOSE 
The purpose of this study, therefore, was to explore the efficacy and effectiveness of 
rapid rate localized heating and lay the foundations for future development of a 
DOX/ICG loaded nanocarrier for targeted drug delivery and therapy. Its 
cytotoxicity and mechanism of action on cancer cell killing/growth inhibition was 
studied. These basic understandings will serve as a foundation for the ultimate 
achievement of targeted chemotherapy-hyperthermia treatment.  
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For this purpose, cell culture experiments in vitro have been conducted on a MDR human 
uterine sarcoma cell line MES-SA/Dx5 and its non-MDR parent cell line MES-SA. Since 
the purpose was to establish the efficacy of the proposed treatment modality on cancer 
cells, normal cell lines were not included. A standard cell culture incubator targeting at 
43 °C was used as the energy source to mimic a slow rate hyperthermia. All the 
experiments were carried out with both hyperthermia delivery modalities.  
It is hypothesized that, if applied at moderate temperature (43 °C), this highly 
localized and rapid heat accumulation will induce necrotic rather than apoptotic cell 
death without triggering cellular protective mechanisms, such as the simultaneous 
induction of MDR and HSP expression, usually associated with slow rate 
hyperthermia targeting at the same temperature. Also, if applied together with 
chemotherapy, a synergistic cell killing is expected through thermal 
chemosensitization, especially in MDR cell lines. 
We expect to see greater and synergistic cell killing/growth inhibition when combining 
chemotherapy with NIR laser-ICG hyperthermia, while HSP expression will maintain at 
the basal level. During this mode of therapy, necrosis will be the major cause of cell 
death; when combining chemotherapy with slow rate incubator hyperthermia, most cells 
will die through the apoptotic pathway.  
III. SPECIFIC AIMS 
Specific Aim 1: Conduct cell culture experiments in vitro to study the level of HSP 
expression in the slow rate (incubator) hyperthermia and rapid rate (NIR laser-ICG) 
hyperthermia to both non-MDR human uterine sarcoma cell line and its MDR variant.  
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Cancer cells acquire thermal tolerance through HSP overexpression. The purpose of 
specific aim 1 is to find out how HSP overexpression is related to the temperature of 
heating, duration of heating and rate of heating.  
In most thermo dosimetry models, such as the widely used CEM 43 °C model, 
temperature and duration of heating are the two parameters that define thermal damage. 
In other words, if two treatments have the same CEM43 value, they should have the same 
cell killing/growth inhibition effect. However, in our preliminary study, we observed 
different hyperthermia chemotherapy interaction with two types of hyperthermia 
delivered at similar thermal dose but at different heating rate [100]. The rapid rate 
photothermal treatment showed synergy to chemotherapy whereas a sub-additive effect 
was found using the slow rate incubator hyperthermia. It is highly possible that the HSP 
was overexpressed in the latter mode of heating and thus protected the cells from being 
damaged by heat stress. Based on this observation, we hypothesize that 1) the rate of 
heating is a determinant factor in causing HSP overexpression; 2) the proposed rapid rate 
NIR laser-ICG hyperthermia could avoid HSP overexpression because the duration of 
treatment is short; 3) the slow rate incubator hyperthermia will cause extensive HSP 
overexpression.  
For this purpose, experiments have been conducted to identify HSP level in different 
hyperthermia treatment regimes. The comparison was between the treatments that have 
similar thermal dose but different heating rate, using the CEM 43°C model. 
Specific Aim 2: Conduct cell culture experiments in vitro to assess the cancer cell 
killing/growth inhibition capability of hyperthermia delivered by incubator and NIR 
laser-ICG system to both non-MDR human uterine sarcoma cell line and its MDR 
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variant. Monitor the initiation and propagation of cell death induced by the two 
different hyperthermia delivery modalities. 
As described before, ICG absorbs laser energy and converts it to heat; therefore, it is 
reasonable to hypothesize that the intracellular binding site of ICG would be the direct 
target in the proposed hyperthermia. The transport kinetics and subcellular localization of 
ICG has been studied extensively by various research groups [98, 101]. Both groups 
showed that ICG is taken up by the cells through a carrier-mediated transport process 
against a concentration gradient. Once the ICG enters the cell, it binds to cytoplasmic 
proteins such as gluthathione S-transferase and ligandin. These proteins will be the direct 
target during the ICG excitation process. Therefore, during the application of NIR laser-
ICG hyperthermia, the temperature at these cellular organelles could be much higher than 
measured at the thermocouple which is placed in the surrounding supernatant.  
We hypothesize that the cancer cell killing/growth inhibition effect induced by incubator 
hyperthermia and NIR laser-ICG hyperthermia are through two different pathways. 
Moderate hyperthermia at 43 °C induced by the incubator is not enough to exert necrosis; 
indirect cellular damage is most likely and apoptotic cell death result from this process; 
while in the NIR laser-ICG hyperthermia, extensive necrotic cell death is expected 
through protein denaturing induced by rapid heat accumulation at the ICG bound cellular 
proteins. Therefore, the purpose of this specific aim is 1) measure the cytotoxicity of both 
hyperthermia delivery methods; then 2) determine the necrotic/apoptotic cell death 
associated with them.   
To fulfill this aim, cytotoxicity assay and apoptotic/necrotic cell death assay to a human 
uterine sarcoma cell line MES-SA and its MDR variant MSE-DA/Dx5 has be carried out. 
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The purpose of incorporating a MDR cell line is to set up a baseline measurement of the 
cytotoxicity of hyperthermia alone for further comparing the cytotoxicity of hyperthermia 
plus chemotherapy in specific aim 3. 
Assays were carried out in the following groups:  
Incubator hyperthermia; 
NIR laser-ICG hyperthermia: 
- ICG alone 
- Laser alone 
- NIR laser-ICG 
The cell proliferation after each treatment was compared to the control group by SRB 
assay, which evaluates the total protein content of the living cells. Apoptotic and necrotic 
cell death was first distinguished by a method using fluorescence microscopy with 
Hoechst 33342 (Invitrogen Corporation, Carlsbad, California) and propidium iodide (PI) 
(Invitrogen Corporation, Carlsbad, California) [102, 103]. Caspase 3 activity was 
monitored as an indicator of cell apoptosis. 
Specific Aim 3: Conduct cell culture experiments to study hyperthermia chemotherapy 
(DOX) interaction with hyperthermia delivered by NIR laser-ICG system to both non-
MDR human sarcoma cell line and its MDR variant. A synergistic cell killing/growth 
inhibition effect is expected. The cytotoxicity of DOX alone was also accessed.  
Different from ICG which is a hydrophilic molecule and taken by the cells through 
carrier-mediated active transport, DOX is lipophilic and transport into the cell is by 
simple diffusion [104]. The membrane permeability is therefore the most important 
parameter in determining DOX intracellular concentration. At elevated temperatures, the 
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cell membrane is found to be more fluidic and unstable. Therefore, it is hypothesized that 
hyperthermia could magnify the cytotoxic effect of DOX through facilitated DOX uptake.  
Generally, a synergistic cell killing/growth inhibition effect is expected in both DOX 
sensitive and MDR cell lines when hyperthermia is applied in combination with DOX. 
However, the situation in MDR cells is more complicated due to the presence of the drug 
efflux pump P-gp. Although hyperthermia could increase DOX uptake in MDR cells, it is 
still unclear whether the increased uptake can last after the temperature returns to 37 °C. 
One group claims that they observed both reduced P-gp and increased membrane 
permeability [1] whereas in other observations, only increased drug uptake by enhanced 
membrane permeability was found during hyperthermia [49]. In this study, the activity of 
P-gp drug efflux pump under heat stress was measured.  
For this purpose, Specific aim 3 has three sub-aims:  
1). Investigate the synergistic cell killing/growth inhibition effect when combining DOX 
with NIR laser-ICG hyperthermia; To fulfill this aim, the SRB assay was used to measure 
cytotoxicity; Synergistic/additive effect was determined by statistical analysis. All these 
tests have been carried out on both DOX sensitive MES-SA cell and its MDR variant 
MES-SA/Dx5.  
Assays were carried out in following groups:  
DOX alone; 
DOX with incubator hyperthermia; 
DOX with NIR laser-ICG 
2) Compare the cellular uptake and intracellular distribution of DOX at normal 
temperature (37 °C) and elevated temperature achieved by either incubator or 
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photothermally activated ICG. DOX uptake by the two cells was determined using a 
fluorescence microscope. This test was performed in the above mentioned groups. 
3) Measure P-gp drug efflux pump activity during and after heat stress delivered by NIR 
laser-ICG hyperthermia 
The calcein-AM test was used to monitor the function of P-gp drug efflux pump during 
and after hyperthermia treatment. Similar with DOX, calcein-AM is a lipophilic non-
fluorescent dye and can penetrate cell membrane by free diffusion. After entering the cell, 
the ester bonds of calcein-AM will be cleaved. This transforms lipophilic non-fluorescent 
calcein-AM to hydrophilic fluorescent calcein, which can no longer diffuse out. P-gp can 
actively transport calcein-AM outside the cell membrane. Therefore, P-gp activity can be 
quantified by calcein fluorescence intensity: non-MDR cells will show strong 
fluorescence while MDR cells will show little fluorescence. 
In order to examine whether hyperthermia down-regulates P-gp activity, the calcein-AM 
assay was performed immediately after NIR radiation. The calcein-AM assay was also 
performed in non-heated drug sensitive cells to serve as a positive control and in non-
heated MDR cells to serve as a negative control. 
IV. METHODOLOGY 
In this section, general cell culture procedures and hyperthermia delivery systems will be 
described as they were used throughout the whole study; then different assays and data 
analysis methods for fulfill each specific aim will be introduced accordingly.  
1. Cell Culture 
All the experiments were carried out by in vitro cell culture studies. A DOX sensitive 
human uterine cancer cell line MES-SA and its MDR variant MSE-SA/Dx5 was 
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purchased from ATCC together with appropriate cell culture medium and serum. Cells 
were grown according to ATCC instructions; detailed cell culture protocols are presented 
in the Appendix, including the preparing of culture medium, cell splitting and cell 
seeding. A Hera Cell incubator which was set at 37°C and supplied with 5% CO2 
provides a standard environment for cell growth. All cell culture experiments were 
carried out in a class 2 biological safety cabinet in sterile treated 96-well plates. 
2. Incubator Hyperthermia Delivery System 
In order to mimic a conventional whole body hyperthermia, a cell culture incubator was 
used as the energy source. The temperature of the incubator was set at 43°C. 96-well 
plates that were originally incubated in the 37°C incubator were transferred to the 43°C 
incubator. Temperature calibration studies were carried out to find out the temperature 
profile of the transferred 96-well plates.  
3. NIR Laser-ICG Hyperthermia Delivery System 
3.1 System Establishment 
For delivering rapid hyperthermia from within the cell, ICG (Cardiogreen, Sigma-Aldrich) 
has to be first delivered into a cell and then activated by a NIR laser. For this purpose, a 
laser heating system was assembled (shown in the following figure). The system was 
comprised of a laser module (RLDH808-1200-5, Roithner Laserthchnik Gmbh), a laser 
holder, a heated stage insert (WPI Heated Stage Insert, World Precision Instruments Inc) 
and a mobile stage with an extension arm. The external cover of the system was also 
designed for safety consideration; power supplies for the laser and the heated stage insert 
are also placed outside the box for the same reason. The system is shown in Figure 2.  
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                              (a)                                                                        (b) 
  
Extension Arm
Position Indicator
                                          (c)                                                  (d) 
Figure 2 NIR laser system for laser-induced hyperthermia. (a) system overview with box cover; 
(b) without cover; power supplies for the laser and the heated stage insert are placed outside 
the box; (c) & (d) different parts of laser system.  
During operation, the whole system was covered in a wooden box to eliminate air 
currents and also to prevent the laser light from exiting. The laser module was fixed to a 
holder so that its beam is perpendicular to the 96-well plate which was placed on the 
heated stage insert. The heated stage insert, placed on a mobile stage positioned directly 
below the laser was powered by an external source to ensure that the plate is at 37°C 
prior to the laser application.   
 40
The NIR laser source emits light at 808 nm with an output power of 1 Watt. Given its 15 
mm2 spot size, the calculated power density is 6.7 W/cm2. This small spot size also 
guaranteed only one well being excited at a time. The exact positioning of a well with the 
laser beam was achieved by moving the stage using the extension arm outside of the box 
as shown in the right side of Figure 2. The arm was used to move the location of the well 
plates thereby allowing different wells to be exposed to the NIR energy one at a time 
without opening the box.  
To verify the positioning of the laser relative to the wells, an infrared beam finder card 
(IRC-42R, Sofradir EC) was used to visualize the NIR laser beam. At the same time, the 
specific well under exposure and its relative position outside the box was indicated by a 
position indicator (another 96-well plate). Laser protection goggles that block NIR light 
were worn by the user during laser operation. Other necessary safety measures were also 
taken, especially appropriate engineering and administrative controls. 
3.2 System Calibration 
A temperature calibration procedure was carried out after the system in Figure 2 was built. 
The purpose was to find out the optimal settings for the heated stage insert controller so 
that a well filled with 230uL of media could be maintained 37°C. The temperature in 
each cell across the entire 96-well plate when using the heated stage insert was measured 
using a thermocouple and recorded. During this calibration process, a 96-well plate filled 
with 230uL of media was placed on the heated stage insert and the settings on the heated 
stage controller adjusted so that the temperature in the well as at 37°C. A 20 minutes time 
interval was allowed for steady temperature to be achieved. Finally, the temperature of 
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each well was recorded to generate a temperature distribution profile of the culture plate. 
The temperature distribution of the 96-well plate is shown in Table 1.  
 1 2 3 4 5 6 7 8 9 10 11 12 
A 29 33 35.8 36.1 36.7 35.9 36.9 36.9 36.8 35.7 33.2 29.8 
B 31.6 34.4 36.8 36.7 37.1 36.6 36.7 36.9 36.5 36.6 34.8 32.7 
C 32.9 35 37.1 37.2 37.3 36.9 37.4 37.3 37.3 37.2 35.7 33.8 
D 33.8 35.6 37.3 37.3 37.1 35.7 36.9 37.4 37.3 37.2 35.7 34.1 
E 33.8 35.5 37.3 37.4 37.2 35.7 37.1 37.3 37.3 37.2 35.9 33.9 
F 33.4 35.4 37 37.1 37.3 36.9 37.3 37.3 37.2 37.1 35.8 33.7 
G 31.1 34.1 36.6 36.7 36.8 36.8 37.6 37.4 37.3 36.6 35.1 31.3 
H 29.1 33.2 35.7 35.9 36.5 36.4 37.1 36.9 36.7 35.8 34.7 29.6 
Table 1Temperature distribution of 96-well plate in the heated stage insert. 
Note that the temperature distribution is not homogenous across the whole plate with the 
peripheral regions lower and central higher. This is because the heated stage is round 
with a hole in the center and the multi-well plate is rectangular. The temperature at wells 
6D and 6E was lower because the heated stage has a whole at that position. Wells with 
temperature ranging from 36.5°C – 37.5°C (bold) were be used for laser studies. 
3.3 Thermal Dose Calculation 
In order to be able to compare the effect of rapid rate hyperthermia with slow rate 
hyperthermia, an isoeffect dose of the two different types need to be calculated. As the 
first step the temperature profile of the two heating modality needed to be obtained.  
3.3.1 Temperature profile of incubator hyperthermia 
The temperature increase during incubator hyperthermia was measured in a 96-well plate 
that was filled with 230 µL of media in a well. The plate was initially kept in a 37 °C 
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incubator and then transferred into the hyperthermia incubator so that the baseline of the 
heating is 37 °C. During the measurement, a thermal couple was placed in the media of a 
well for temperature recording. The incubator was set at 43 °C and 50 °C and the 
temperature profile obtained from both cases. 
3.3.2 Temperature profile of laser-ICG hyperthermia 
This procedure was carried out with the liquid in the wells initially at 37 °C to find out an 
optimal concentration at which ICG is not cytotoxic when it is not excited while it is able 
to produce a peak temperature of 43 °C or 50 °C. 
30 µL of ICG at concentrations of 7.7 µM, 38.5 µM, and 77 µM was added to the wells 
that were originally loaded with 200 µL media to achieve final concentrations of 1 µM, 5 
µM, and 10 µM, respectively. Wells were then excited by the NIR laser and their 
temperature profiles obtained using a thermal couple placed inside the well.  
After obtaining the temperature profile during both incubator and laser-ICG hyperthermia, 
the CEM43 model was applied to calculate the thermal doses in each treatment.      
4. The Fulfillment of Specific Aim 1 
Specific Aim 1: Conduct cell culture experiments in vitro to study the level of HSP 
expression in the slow rate (incubator) hyperthermia and rapid rate (NIR laser-ICG) 
hyperthermia to both non-MDR human uterine sarcoma cell line and its MDR variant.  
Heat-caused damage may be weakened by HSP overexpression. HSP could protect cells 
from heat induced damage by stabilizing unfolded or misfolded peptides and giving cells 
time to repair or re-synthesize damaged proteins. This specific aim will test HSP 
expression in both incubator hyperthermia and NIR laser-ICG hyperthermia.  
 43
The 70 kilodalton heat shock proteins (HSP70s) are the focus in this part of the research 
because they provide thermotolerance to cells exposed to heat stress. An Enzyme-Linked 
Immuno Sorbent Assay (ELISA) was used to detect the expression of HSP using an 
antigen that can specifically detect HSP. Basal level HSP expression was identified in the 
cells incubated at normal temperature (37 °C). At 43 °C, the level of HSP in NIR laser-
ICG hyperthermia treated cells is expected to be the same as in cells incubated in 37 °C; 
while elevated HSP expression is expected in cells incubated in a 43 °C incubator. At 50 
°C, both slow rate incubator hyperthermia and rapid rate laser-ICG hyperthermia should 
have similar HSP levels compared to cells maintained at 37 °C. 
4.1 HSP Expression in 43 °C & 50 °C 
The procedure for this experiment is as follows: at the first day, cells were seeded, and 
allowed 24 hours to attach and stabilize. At the second day, cells were divided into 2 
groups. Group1: no treatment was given and HSP level was quantified as negative control; 
Group2 cells were exposed to different hyperthermia treatments. The ELISA assay was 
used on both Group1 and Group2 cells 1, 3, 6, 12 and 24 hours after they received the 
hyperthermia treatment. Wells that contained only media were also included to provide a 
background measurement and subtracted from the wells containing both cells and media. 
4.1.1 Cell seeding  
When the cells reached a sufficient confluency, which was determined by viewing the 
culture flasks under an optical microscope, they were first detached by trypsin-EDTA 
solution and then counted with the aid of a hemocytometer under the microscope for cell 
density calculation. After removing the trypsin-EDTA and resuspending with culture 
media, cells were transferred to 96 well plates at a concentration between 5,000-8,000 
 44
cells per well (200 μL cell-medium suspension). Detailed cell seeding diagram in 96-well 
plates for both hyperthermia will be discussed below. 
1) Cell seeding in 96-well plate for incubator hyperthermia 
Table 2 gives a schematic diagram of cell seeding when using incubator hyperthermia. 
Compared to NIR laser-ICG hyperthermia where wells are treated one by one, cell 
seeding in incubator hyperthermia is quite simple. Basically any group of wells can be 
used because heat is delivered to the wells simultaneously.  
 1 2 3 4 5 6 7 8 9 10 11 12 
A             
B             
C M ○ ○ ○ ○        
D M ○ ○ ○ ○        
E M ○ ○ ○ ○        
F M ○ ○ ○ ○        
G             
H             
Table 2  Cell seeding diagram for incubator hyperthermia; cell density: 5000-8000 cells/well.  
M: wells with only media; ○: wells with cells. 
2) Cell seeding in 96-well for NIR laser-ICG hyperthermia 
Table 3 gives a schematic diagram of cell seeding when using laser-ICG hyperthermia. 
Since wells are treated one by one in this circumstance, it is important to maintain other 
wells at normal temperature while one well is under laser exposure. Therefore, cells were 
seeded differently compared to the incubator hyperthermia. A schematic cell seeding 
diagram is shown in Table 3. In order to eliminate any potential for laser-light cross talk, 
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the neighboring 8 wells of any single well are left blank if that well is going to receive 
laser treatment.  
 1 2 3 4 5 6 7 8 9 10 11 12 
A Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ Δ 
B Δ          Δ Δ 
C M  ○  ○  ○  ○  Δ Δ 
D M          Δ Δ 
E M  ○  ○  ○  ○  Δ Δ 
F M          Δ Δ 
G Δ  ○  ○  ○  ○  Δ Δ 
H Δ          Δ Δ 
Table 3 Schematic cell seeding diagram for laser-ICG induced hyperthermia; cell density: 
5000-8000 cells/well.  M: wells with only media; ○: wells capable of receiving laser treatment; 
Δ: peripheral region which could be used for control cells.  
4.1.2 Hyperthermia treatment 
1) Incubator being the energy source for hyperthermia  
Hyperthermia treatment was given 24 hours after cell seeding. During hyperthermia 
treatment, the incubator was set either at 43 °C or 50 °C. 60 minutes incubation was 
given to 43 °C hyperthermia treated wells while 30 minutes incubation was given to 50 
°C hyperthermia treated wells.  
2) NIR laser being the energy source for hyperthermia 
24 hours after cell seeding, 30 µL of ICG at concentrations of 38.5µM or 77 µM was 
added to the wells that were originally loaded with 200 µL media to achieve 5µM or 10 
µM final concentration; then the plate was returned to the standard cell culture incubator 
for 2 hours which allowed for the homogenous distribution of ICG in the well. Next, 3 
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minute laser treatment was applied to each concentration to achieve 43 °C or 50 °C 
hyperthermia. These concentrations of ICG were chosen because when exposed to the 
laser for 3 minutes, they each produced a thermal dose which is similar to 60 minutes 43 
°C incubator hyperthermia or 30 minutes 50 °C incubator hyperthermia. After 
hyperthermia treatment, the plate was returned to the standard cell culture incubator.  
4.1.3 ELISA assay 
ELISA was performed to identify the HSP70 level 1, 3, 6, 12, 24 hours after 
hyperthermia application. 
A brief description of the assay procedure is as follows: inducible HSP70 is captured by a 
specific mouse monoclonal antibody which has been pre-coated on the HSP70 
Immunoassay plate and then detected with an HSP70 specific rabbit polyclonal antibody. 
A secondary antibody, horseraidish peroxidase conjugated anti-rabbit IgG, is used to bind 
to this rabbit polyclonal antibody. Tetramethylbenzidine (TMB) substrate then reacts 
with horseradish peroxidase to give a blue color in proportion to the amount of captured 
Hsp70. The color development is stopped with acid stop solution which converts the 
endpoint color to yellow. The intensity of the color is measured in a microplate reader at 
450 nm and quantified with an arbitrary value. The actual concentration could be 
interpreted with a calibration curve.  
5. The Fulfillment of Specific Aim 2 
Specific Aim 2: Conduct cell culture experiments in vitro to assess the cancer cell 
killing/growth inhibition capability of hyperthermia delivered by incubator and NIR 
laser-ICG system to both non-MDR human uterine sarcoma cell line and its MDR 
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variant. Monitor the initiation and propagation of cell death induced by the two 
different hyperthermia delivery modalities. 
Specific Aim 2 has 2 sub-aims, which are 1) identify the cytotoxicity induced by the two 
hyperthermia delivery methods; 2) investigate the necrotic/apoptotic cell death associated 
with the two hyperthermia delivery methods. These aspects will be discussed respectively 
in the following section. 
5.1 Cytotoxicity Assessment to both Incubator Hyperthermia and NIR Laser-ICG 
Hyperthermia 
Cytotoxicity assessment was based on cell proliferation after hyperthermia treatment. The 
procedure of the experiment is as follows: on the first day, cells were seeded, and then 
allowed 24 hours to attach and equilibrate; on the second day, wells were divided into 3 
groups. Group1: the total number of cells was quantified as the initial value.  Group2 
cells was subjected to different hyperthermia treatments and returned to the 37 ºC 
incubator for 24 hours growth. Group3 cells served as a negative control and no treatment 
was given; on the third day, cell proliferation of both Group2 and Group3 cells were 
quantified by SRB assay, which measures the total cellular protein as an indicator of cell 
proliferation. Wells that contain only media was included as background and the 
absorbance measurement subtracted from that of the wells containing both cells and 
media. 
5.1.1 Cell seeding  
See section IV.4.1.1.  
5.1.2 Hyperthermia treatment  
1) Incubator being the energy source for hyperthermia  
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24 hours after cell seeding, the 96-well plates for studying the cytotoxicity of incubator 
delivery of hyperthermia was removed from the 37 ºC (standard) incubator and put into 
the 43 °C incubator for 60 minutes. After treatment, the plate was returned to the 37 ºC 
cell culture incubator for an additional 24 hours. 
2) NIR laser being the energy source for hyperthermia 
24 hours after cell seeding, 30 µL of ICG at concentrations of 38.5 µM was added to the 
wells that were originally loaded with 200 µL media to achieve 5 µM final concentration; 
then the plate was returned to the standard cell culture incubator for 2 hours which 
allowed for the homogenous distribution of ICG in the well. Next, 3 minute laser 
treatment was applied to elevate temperature. After hyperthermia treatment, the plate was 
returned to the standard cell culture incubator for 24 hours. 
5.1.3 SRB assay  
Cell proliferation was measured by SRB assay. In this study, SRB assay was given to 
group1 cells 24 hours after cell seeding and to group2 and group3 cells 24 hours after 
they receive hyperthermia treatment. Cells were first fixed to the bottom of 96-well plate 
with 10% (wt/vol) trichloroacetic acid (TCA) for 30 minutes. The plates were then 
washed with water for 3 times. After washing, Sulforhodamine-B (SRB) dye which binds 
to cellular proteins was added at a concentration of 0.4% (wt/vol) for cell staining. The 
staining procedure was 30 minutes followed by 3 times washing using 1% (vol/vol) 
acetic acid which removed the unbound SRB dye in the plate. Lastly, the protein-bound 
SRB was extracted by 10 mM Trizma-base and the absorbance of dissolved SRB dye was 
measured at 530 nm using the TECAN fluorometer (Tecan Systems Inc, San Jose, 
Califonia). This value was then background subtracted (from media only wells) and 
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compared with controls, which are the SRB values of cells without any treatment for 
obtaining cell growth.  
5.2 Apoptotic/Necrotic Cell Death Detection to both Incubator Hyperthermia and NIR 
Laser-ICG Hyperthermia 
The purpose is to evaluate the extent of apoptosis and necrosis associated with each 
hyperthermia treatment.  
5.2.1 Cell seeding & hyperthermia treatment  
See section IV. 4.1.1 & section IV.5.1.2. 
5.2.2 Cell apoptosis/necrosis assay  
24 hours after treatment, apoptosis/necrosis assay was performed to study the mode of 
cell death caused by the treatment. Two different assays were used to detect apoptotic 
and necrotic cell death. 
1) apoptosis/necrosis detection based on fluorescence imaging 
Apoptotic and necrotic cell death was distinguished by a method using fluorescence 
microscopy with Hoechst 33342 (Invitrogen Corporation, Carlsbad, California) and 
propidium iodide (PI) (Invitrogen Corporation, Carlsbad, California) [102, 103]. After 
hyperthermia treatment, cells were stained with 10 µg/ml of Hoechst 33342 and 10 µg/ml 
of PI for 5 min and analyzed under an Olympus IX81 fluorescent microscope at 20X and 
60X magnification (Olympus America Inc. Pennsylvania). Hoechst 33342 stained all 
nuclei and PI stained only the nuclei of cells with a disrupted plasma membrane. Nuclei 
of viable, necrotic and apoptotic cells was observed under fluorescence microscopy as 
round blue nuclei, round pink nuclei and fragmented blue or pink nuclei, respectively. 
2) Quantitative Fluorometric Assay of Caspase 3 Activity as an Indicator of Apoptosis  
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It has been shown that the initiation all intracellular events during apoptosis is 
characterized by the activation of a family of specific proteases called cysteinyl-aspartic-
acid-proteases (caspases) [105]. To date, human caspase family includes twelve different 
caspases. Among them, caspase 3 is found responsible for the cleavage and activation of 
caspase 6, 7. These three effector caspases directly initiate apoptosis by cleaving specific 
protein substrates within the cell [106].  
Since the activation of caspase 3 is a unique and universal event for the initiation of all 
intracellular events in cell apoptosis, cellular caspase 3 level was monitored as an 
indicator to support the results from the fluorescence assay. 
The Caspase 3 Assay kit, Fluorimetric (Sigma-Aldrich, St. Louis, Missouri) was used for 
this purpose. This assay is based on the hydrolysis of the peptide substrate acetyl-Asp-
Glu-Val-Asp-7-amido-4-methylcoumarin (Ac-DEVD-AMC) by caspase 3. Once Ac-
DEVD-AMC is hydrolyzed by caspase 3, 7-amino-4-methylcoumarin (AMC) moiety is 
released, which could be detected by its fluorescence. The excitation and emission 
wavelengths of AMC are 360 nm and 460 nm, respectively. This assay was performed in 
96-well plates and the fluorescence signal was measured by a TECAN fluorometer. 
6. The Fulfillment of Specific Aim 3 
Specific Aim 3: Conduct cell culture experiments in vitro to study hyperthermia 
chemotherapy (DOX) interaction with hyperthermia delivered by incubator as well as 
NIR laser-ICG system to both non-MDR human uterine sarcoma cell line and its MDR 
variant. A synergistic cell killing/growth inhibition effect is expected. The cytotoxicity 
of DOX alone was also accessed.  
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6.1 Synergistic Cell Killing/Growth Inhibition Measurement in DOX-Hyperthermia 
Combinational Treatment  
To fulfill this aim, SRB assay for detecting the cytotoxicity of DOX in combination with 
hyperthermia treatment was carried out on DOX sensitive MES-SA cell and its MDR 
variant MES-SA/Dx5.  
The methodology used here was the same as in detecting the cytotoxicity of hyperthermia 
alone. The difference is that, DOX was given together with the hyperthermia treatment 
24 hours after cell seeding. 
The procedure of the experiment is as follows: on the first day, cells were seeded, and 
then allowed 24 hours to attach and stabilize; on the second day, cells were divided into 3 
groups. Group1: SRB assay performed to measure the initial cell amount.  Group2 cells 
were treated with DOX-hyperthermia combination and allowed 24 hours of growth. 
Group3 cells served as a negative control and no treatment was given; on the third day, 
cell proliferation of both Group2 and Group3 cells was quantified by SRB assay, which 
measures the total viable cellular protein as an indicator of cell proliferation. SRB assay 
was also performed on wells that contain only media (background) and subtracted from 
wells containing both cells and media. 
6.1.1 Cell seeding 
See section IV 4.1.1. 
6.1.2 DOX-hyperthermia combinational treatment  
1) DOX alone without hyperthermia 
24 hours after cell seeding, 30 µL of 0.77µM, 7.7 µM and 77 µM of DOX was given to 
the cells. Since the wells were originally loaded with 200 µL of media, the final 
 52
concentration of DOX in the well was 0.1 µM, 1 µM and 10 µM. Then the plate was 
returned to the standard cell culture incubator prior to SRB assay. 
2) Incubator being the energy source for hyperthermia 
24 hours after cell seeding, 96-well plates for studying the cytotoxicity of incubator 
hyperthermia was removed from the standard cell culture incubator. 30 µL of 0.77 µM, 
7.7 µM and 77 µM of DOX was given to the cells. Since the wells were originally loaded 
with 200 µL of media, the final concentration of DOX in the well was 0.1 µM, 1 µM and 
10 µM. After adding the drug, plate was placed into the 43 °C incubator for 60 minutes. 
After treatment, the plate was returned to the standard cell culture incubator. 
3) NIR laser being the energy source for hyperthermia 
ICG for heating and DOX for chemotherapy was given to the cancer cells. Then DOX 
was added to the wells. 1 minute laser exposure was followed to study hyperthermia-
chemotherapy interaction. 24 hours after cell seeding, 30 µL of ICG at a concentration of 
43.3 µM was added to the wells, and then 30 µL of 0.86 µM, 8.6 µM and 86 µM of DOX 
was given to the cells. The resulting final concentration of ICG in the well was 5 µM and 
the DOX concentration was 0.1 µM, 1 µM and 10 µM respectively. After loading DOX 
and ICG, the plate was returned to the standard cell culture incubator for 2 hours prior to 
the 1 minute laser treatment, which elevated the temperature to 43 °C. After hyperthermia 
treatment, the plate was returned to the standard cell culture incubator for 24 hours. 
6.1.3 SRB assay  
1) Cytotoxicity of DOX-hyperthermia combinational treatment 
Cell proliferation was measured by SRB assay. In this study, SRB assay was given to 
group1 cells 24 hours after cell seeding and to group2 and group3 cells 24 hours after 
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they received hyperthermia-chemotherapy treatment. SRB assay was performed as 
described in section IV.5.1.3. 
6.2 Cellular Uptake and Intracellular Distribution of DOX in 37 °C and 43 °C Achieved 
by Incubator or NIR laser-ICG Hyperthermia 
This assay was carried out in both 37°C and 43°C to compare the kinetics of cellular 
uptake of DOX and its direct target site.  
24 hours after cell seeding (see section IV 4.1.1), 30 µL of DOX at concentrations of 77 
µM was added to the wells that were originally loaded with 200µL media to achieve a 
final concentration of 10 µM. Hyperthermia treatment was given immediately after the 
addition of DOX. Cells were observed under an Olympus IX81 fluorescent microscope 
(Olympus America Inc. Pennsylvania) equipped with a U-MNB2 (Olympus America Inc. 
Pennsylvania) filter cube which excites at 470-490 nm and collects the fluorescence 
signal with a 520 nm long pass filter. Images were taken 1 hour and 24 hours after 
hyperthermia treatment and compared with their respective controls, which were treated 
with DOX but not hyperthermia.  
6.3 P-gp Drug Efflux Pump Activity after 43°C Hyperthermia Delivered by NIR laser-
ICG or Incubator 
Calcein-AM assay was used to asses P-gp function after hyperthermia. If the drug 
extruding capability of P-gp is impaired under heat stress, more calcein-AM can diffuse 
into the cell and be transformed to calcein. Therefore, intracellular calcein fluorescence 
intensity can be used as an indicator of P-gp function. In this study, the calcein-AM test 
was given to heat treated and non-treated MDR cells (MES-SA/Dx5) as well as 37°C 
incubated drug sensitive cells (MES-SA).  
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The procedure for the experiment is as follows: on the first day, cells were seeded, and 
then allowed 24 hours to attach and stabilize; on the second day, cells were divided into 3 
groups. Group1 were DOX sensitive MES-SA cells. Calcein-AM assay was performed to 
group1 cells without any DOX or hyperthermia treatment. Strong fluorescence intensity 
is expected since there are no P-gp proteins in these cells. Group2 cells are MDR cells 
MES-SA/Dx5. They were first treated with NIR laser-ICG hyperthermia and then tested 
with the celcein-AM assay. Group3 cells were also MDR cells but they were assessed by 
calcein-AM assay without any DOX or hyperthermia treatment. Since MES-SA/Dx5 
cells are P-gp abundant, a low level of fluorescence intensity is expected. 
6.3.1 Cell seeding 
See section IV.4.1.1. 
6.3.2 NIR laser-ICG hyperthermia treatment to MDR cells 
See section IV.5.1.2. 
6.3.3 Calcein-AM assay  
Calcein-AM assay was given to Group1 and Group3 cells 24 hours after cell seeding. For 
group2 cells, calcein-AM assay was given immediately after NIR irradiation. 
7. Data Analysis 
In this section, data processing methods associated with each assay will be described. 
Differences and significance among each treatment was tested by statistical analysis. 
7.1 Cytotoxicity and Synergistic/Additive Effect Determination 
SRB assay was used to measure cell proliferation. Cytotoxicity was obtained in the 
following treatment groups: 
Incubator hyperthermia; 
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ICG alone; 
Laser alone; 
NIR laser-ICG hyperthermia; 
DOX alone; 
DOX + incubator hyperthermia; 
DOX + ICG; 
DOX + Laser; 
DOX + NIR laser-ICG; 
Percentage of cell killing/growth inhibition for each treatment group was calculated 
according to the method described by Monks et al. [107]. Denoting initial SRB value as 
T0, control SRB value as C and treatment SRB value as T: 
cell survival , if    (Equation 3) 0 0( ) /( )*100S T T C T   0T T
cell killing , if 0 0( ) /( )*100K T T C T   0T T        (Equation 4) 
Note that two equations have been used [107]. If , the treatment could be 
considered as growth inhibition; if 
0T T
0T T , there is no net growth after the treatment, its 
effect could be considered as cell killing. 
Synergistic effect was determined with the assumption that both DOX and hyperthermia 
treatment have exponential dose-response curves in cancer cells [108] and calculated by a 
method described by Berenbaum [109]. Denoting the cytotoxicity of DOX alone as E(D), 
hyperthermia alone as E(H) and the combinational treatment as E(D,H), synergistic effect 
could be assumed if:  
E(D,H) > E(D) + E(H) - E(D) E(H) , (Equation 5) 
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where E = 1 - S when , and E = K when 0T T 0T T . The data was then analyzed by 
ANOVA test with bonferroni post-hoc correction when the comparisons were made 
between more than two samples. When comparison was between two samples, the t-test 
was used. The combinational treatment is considered synergistic at a significance level of 
α = 0.05 for both ANOVA and t-test. 
7.2 Caspase 3 & HSP70 Activity 
Caspase 3 assay was used to quantify apoptosis. The extent of apoptosis in incubator 
hyperthermia or NIR laser-ICG hyperthermia was compared to non-treated cells as 
described in section IV.5.2.2. If denoting caspase 3 quantity in control cells as C, 
hyperthermia treated as T, apoptosis could be calculated as follows: 
( ) / *100T C C ,   (Equation 6) 
Percentage increase of HSP expression treated with incubator hyperthermia or NIR laser-
ICG hyperthermia was also calculated according to Equation 6. Calculated percentage 
increase in cell apoptosis/HSP expression was then analyzed by ANOVA test with 
bonferroni post-hoc correction when the comparisons were made between more than two 
samples. When comparison was between two samples, the t-test was used. Differences 
were considered significant when p<0.05 for both tests. 
V. RESULTS 
1. Selection of Isoeffect Dose  
1.1 Temperature Profile during Laser-ICG Hyperthermia 
As shown in Figure 3, the heat production of ICG was highly concentration dependant. 
More ICG generated more heat. Heat rapidly accumulated during the first 30 seconds of 
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laser application and reached maximum at about 3 minutes, then the temperature dropped 
slowly probably due to photo bleaching.  
Temperature profile during laser-ICG hyperthermia
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Figure 3 Heat generation as a function of ICG concentration (n=3).  
Without ICG, about 2 °C increase was observed with the current laser setting, which is 
due to the thermocouple absorbing laser energy. This temperature increase was subtracted 
from the actual temperature profile of laser-ICG hyperthermia when calculating the 
thermal dose. The cytotoxicity assay indicated that the laser exposure itself with ICG did 
not affect cancer cell proliferation (shown in Figure 6).  During the 3 minutes, 2.5 µM, 5 
µM and 10 µM ICG produced peak temperatures of about 40 °C, 43 °C and 50 °C 
respectively, after subtracting the temperature increase due to the thermocouple. 
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1.2 Temperature Profile during Incubator Hyperthermia 
As shown in Figure 4, the temperature increase rate in the incubator hyperthermia is 
much slower than the temperature increase rate observed during ICG/laser exposure. The 
reason could be that, in incubator hyperthermia, heat has to be first absorbed by the tissue 
culture flask and then diffuse into the wells. The plastic well plate apparently acts as a 
huge heat sink. It absorbed heat energy and transferred the energy gradually to the media; 
whereas in laser ICG hyperthermia, heat was produced directly from the ICG solution. 
Temperature profile during incubator hyperthermia
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Figure 4 Heat generation as a function of ICG concentration (n=1). 
1.3 Thermal Dose Calculation  
Table 4 lists calculated CEM43 for several different hyperthermia treatments. In this study, 
the effect of “5 µM ICG + 3 min laser” was compared to “43°C incubator 1h”, while “10 
µM ICG + 3 min laser” was compared to “50°C incubator 30 min” because the two 
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treatment pairs have similar temperature and total thermal dose. Thus, any difference 
produced by these two pairs will be because of the rate of heating.  
Treatment type CEM43 (min) 
5 µM ICG + 3 min laser 6.2 
10 µM ICG + 3 min laser 331.0 
43°C incubator 1h 23.5 
45°C incubator 1h 116.4 
50°C incubator 1h 2706.7 
50°C incubator 30 min 371.4 
Table 4 Calculated CEM43 in different types of hyperthermia treatment, based on the 
temperature curves in Figure 3&4 and Equation 2. 
2. HSP Level  
HSP70 expression after different types of hyperthermia is shown in Figure 5. ELISA was 
repeated three times for each data point shown in the figure; each assay contains two 
repetitions. According to the assay protocol, the measured absorbance value at 450 nm 
(OD 450) represents the amount of HSP70. Since the cell growth was inhibited after 
hyperthermia treatment, which may affect the total cellular HSP, the obtained HSP70 
absorption values were corrected using the SRB toxicity absorption value to account for 
changes in cellular protein for a particular treatment. Briefly, after obtaining cell SRB 
value, the HSP70 values from each treatment group were normalized to the ratio of the 
SRB value from that treatment to the SRB value from the control, that is, from cells that 
did not receive any treatment. We observed that the baseline HSP70 level in the MDR 
positive MES-SA/Dx5 cells is about two times higher than in the non-MDR MES-SA 
cells when both cells were cultured in normal temperature (37 ºC). Since the two cells 
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were seeded at the same density and given that they have similar doubling time, this 
increased baseline HSP70 expression in the MES-SA/Dx5 cell suggests a correlation 
between MDR and heat resistant.  
HSP 70 level after hyperthermia treatment
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Figure 5 HSP70 expression after different types of hyperthermia treatment (n=3). Data were 
normalized as described above. “” Significantly higher cellular HSP70 level among the three 
groups by ANOVA test with bonferroni post-hoc correction. 
When comparing different hyperthermia treatments, increased HSP70 expression was 
observed in 1 hour 43 ºC incubator hyperthermia treatment. The treatment promoted 
HSP70 expression in both MDR and non-MDR MES-SA cells. After the treatment, the 
HSP70 level in MES-SA/Dx5 cell was still higher than in MES-SA cell; however the 
percentage increase is higher in MES-SA cell than in MES-SA/Dx5 cell. About a 70% 
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increase was observed in MES-SA/Dx5 cell, whereas the HSP70 level in MES-SA cell 
was more than doubled.  
3. Cytotoxicity of Incubator Hyperthermia and NIR Laser-ICG Hyperthermia 
3.1 Cytotoxicity of NIR Laser-ICG Hyperthermia 
ICG is considered safe and has been approved by the FDA for some clinical uses for over 
50 years. Our data suggested ICG did not affect cell growth at a wide range of 
concentrations as shown in Figure 6. ICG was slightly toxic only at high concentrations. 
As shown in the figure, “*” indicates statistical significance. Statistical analysis was 
performed by comparing each treatment value with the control value, which did not 
receive any treatment. Cell growth was inhibited at 100 µM ICG concentration in both 
MES-SA and MES-SA/Dx5 even without exposure to NIR irradiation. Although MES-
SA cell growth was inhibited at 50 µM ICG concentration, considering that the inhibition 
is only 15% we can conclude that 5 µM or 10 µM ICG itself should be safe to the cells.  
 62
24h ICG incubation
0
0.2
0.4
0.6
0.8
1
1.2
0 5 10 50 100
ICG Concentration (µM)
N
et
 G
ro
w
th
 (f
ra
ct
io
n)
MES-SA MES-SA/DX5
*
* *
 
Figure 6  ICG cytotoxicity in MES-SA and MES-SA/Dx5 cells without laser exposure (n=4). * 
P < 0.05 (by paired t-test) between samples and control (cells without any treatment), indicating 
significant difference due to high concentration of ICG. 
Figure 7 shows the cytotoxicity of NIR laser-ICG hyperthermia alone without DOX. “0” 
ICG concentration means 30 µL of DPBS without ICG was added to the wells. No 
differences could be detected when ICG was not present in the wells, indicating that the 
laser radiation itself did not affect cell growth. Cell proliferation was significantly lower 
when ICG was present. In contrast, ICG alone at 5µM was not toxic. The data clearly 
indicates the cytotoxicty effect of ICG when excited with NIR radiation. Note that no 
difference could be detected between treated MES-SA and MES-SA/Dx5 cells suggesting 
that these two cell lines have similar sensitivity toward 3 minute laser-ICG hyperthermia 
treatment aside from the fact that MES-SA/Dx5 is a MDR cell line while MES-SA is not. 
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Figure 7 Cytotoxicity of NIR laser-ICG hyperthermia (n=4). “*” symbol indicates statistical 
significance. Statistical analysis was performed by comparing each treatment to control (0 ICG 
concentration), with paired t-test (α = 0.05).    
3.2 Cytotoxicity of Incubator Hyperthermia  
The cytotoxicity of 1 hour 43 °C incubator hyperthermia is shown in Figure 8. In order to 
be able to compare with DOX treatment, in which DOX was dissolved in 30 μL of DPBS, 
30 μL of DPBS was added to the cells prior to treatment as the “0” concentration. 
Compared to control cells, the addition of 30 μL of DPBS did not affect cell growth at 
normal temperature (37 °C). The 1 hour 43 °C incubator hyperthermia treatment caused 
about 25% cell growth inhibition in MES-SA cell and 15% in MES-SA/Dx5 cells. 
However, no statistical significance could be detected between the two cells.  
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Cytotoxicity of 1 h 43 °C incubator hyperthermia
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Figure 8 Cytotoxicity of 1hour 43 °C hyperthermia (n=4). “*” symbol indicates statistical 
significance. Statistical analysis was performed by comparing each treatment to control (37 °C), 
with paired t-test (α = 0.05).    
4. Cytotoxicity of the Combinational Treatment  
In order to determine whether there is a synergistic effect when combining DOX and 
hyperthermia, the predicted additive effect was calculated by subtracting the effect of 
each “hyperthermia alone” (no DOX) treatment from the “DOX only” (no hyperthermia) 
group. Specifically, for incubator hyperthermia, the predicted additive effect of 
combining incubator hyperthermia with DOX was calculated by subtracting the 
cytotoxcity of “incubator hyperthermia alone” from “DOX alone”; for laser-ICG 
hyperthermia, the predicted additive effect of combining laser-ICG hyperthermia with 
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DOX was calculated by subtracting the cytotoxcity of “laser-ICG hyperthermia alone” 
from “DOX + 5 µM ICG” group. 
4.1 Cytotoxicity of DOX Chemotherapy with 1 hour 43 °C Incubator Hyperthermia 
The effect of combining DOX chemotherapy and 1 hour 43 °C incubator hyperthermia on 
MES-SA and MES-SA/Dx5 cells is shown in Figures 9-10 respectively.  
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Figure 9 Cytotoxicity of DOX alone and DOX in combination with incubator hyperthermia on 
MES-SA cells (n=4). “**”: statistical significance between “DOX alone” group and “DOX + 1 
h 43 °C incubator” group or between “DOX + 1 h 43 °C incubator” group and the calculated 
additive effect by parried t-test (α = 0.05). 
As shown in Figure 9, the MES-SA cell proliferation in the DOX + incubator 
hyperthermia group and DOX alone group decreased with increasing DOX concentration. 
When comparing the two treatment groups, DOX in combination with incubator 
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hyperthermia is more toxic than DOX itself at all DOX concentrations except at 10 μM. 
The reason is probably due to the fact that MES-SA cells are DOX sensitive and 10 μM 
DOX itself is so toxic to the cells that the addition of hyperthermia did not magnify the 
cytotoxic effect. Synergistic effect was observed at 1 μM DOX concentration only.  
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Figure 10 Cytotoxicity of DOX alone and DOX in combination with incubator hyperthermia on 
MES-SA/Dx5 cells (n=4). “**”: statistical significance between “DOX alone” group and 
“DOX + 1 h 43 °C incubator” group or between “DOX + 1 h 43 °C incubator” group and the 
calculated additive effect by parried t-test (α = 0.05). 
Figure 10 shows the cytotoxcity of DOX + incubator hyperthermia group and DOX alone 
group to MES-SA/Dx5 cells. Again, decreased cell number with increasing DOX 
concentration was observed. When comparing the two treatment groups, unlike in MES-
SA cells, in MES-SA/Dx5 cells, DOX in combination with incubator hyperthermia is 
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more toxic than DOX itself at all DOX concentrations except at 0.1 μM. When 
comparing the actual cytotoxicity produced by the combinational treatment with the 
predicted additive effect value, we observed synergistic cell killing with increasing DOX 
concentration at both 1 μM and 10 μM, while at 0.1 μM DOX concentration, the 
interaction between incubator hyperthermia and DOX was additive.  
4.2 Cytotoxcity of DOX Chemotherapy with Laser (3 minutes) - ICG (5 μM) 
Hyperthermia 
Figures 11-12 show the cytotoxcity of DOX + laser-ICG hyperthermia compared to DOX 
alone. For both MES-SA and MES-SA/Dx5 cells, decreased cell number with increasing 
DOX concentration was observed. Greater cell growth inhibition was achieved by 
simultaneous administration of DOX and NIR laser hyperthermia. Cytotoxcity of the 
combined treatment modality is larger than DOX alone or hyperthermia alone. When 
comparing the actual cytotoxicity produced by the combinational treatment with the 
predicted additive effect value, synergistic cell killing/growth inhibition was observed at 
1 μM DOX concentrations in DOX sensitive MES-SA cells and at all DOX 
concentrations in MDR MES-SA/Dx5 cells.   
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Cytotoxicity of DOX + laser-ICG hyperthermia on MES-SA 
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Figure 11 Cytotoxicity of DOX alone and DOX in combination with laser-ICG hyperthermia 
on MES-SA cells (n=4). “**”: statistical significance between “DOX alone” group and “DOX 
+ 5 μM ICG + 3 min laser” group or between “DOX + 5 μM ICG + 3 min laser” group and the 
calculated additive effect by parried t-test (α = 0.05). 
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Figure 12 Cytotoxicity of DOX alone and DOX in combination with laser-ICG hyperthermia 
on MES-SA/Dx5 cells (n=4). “**”: statistical significance between “DOX alone” group and 
“DOX + 5 μM ICG + 3 min laser” group or between “DOX + 5 μM ICG + 3 min laser” group 
and the calculated additive effect by parried t-test (α = 0.05). 
Figures 13-14 summarize the cytotoxicity of different treatments on MES-SA and MES-
SA/Dx5 cells respectively. An ANOVA test with bonferroni post-hoc correction 
suggested that there is no difference among DOX alone group, DOX with ICG but 
without laser group and DOX with laser but without ICG group in either cell line, which 
is expected because ICG alone should not change DOX activity and laser itself without 
ICG does not produce hyperthermia. When comparing the two hyperthermia treatments 
by paired t-test, laser-ICG hyperthermia achieved better chemotherapy-hyperthermia 
interaction at 10 µM DOX concentration in MES-SA cells. However, this difference fails 
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to reach statistical significance when ANOVA was applied to all the five treatment 
groups with bonferroni post-hoc correction. At other concentrations, no difference could 
be detected between cells treated by the two hyperthermia delivery methods.  
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Figure 13 Cytotoxicity of different treatments on MES-SA cells (n=4). “**”: statistical 
significance by comparing “DOX + 5 μM ICG + 3 min laser” group to “DOX + 1 h incubator 
hyperthermia” group by parried t-test (α = 0.05); this difference fails to reach statistical 
significance when ANOVA is applied to all the five treatment groups.   
As to the MES-SA/Dx5 cell (Figure 14), laser-ICG hyperthermia achieved better 
chemotherapy-hyperthermia interaction than did incubator hyperthermia at 0.1 µM DOX 
concentration in MES-SA/Dx5 cells both by paired t-test and ANOVA. At all the other 
concentrations, laser-ICG hyperthermia showed no statistically significant difference 
compared to incubator hyperthermia. 
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Figure 14 Cytotoxicity of different treatments on MES-SA/Dx5 cells (n=4). “”: statistical 
significance among the groups by ANOVA with bonferroni post-hoc correction (α = 0.05). 
5. Cell Death Pathway: Apoptosis/Necrosis 
5.1 DOX Induced Apoptosis  
In this experiment, MES-SA and MES-SA/Dx5 cells were treated with 1 μM or 5 μM 
DOX for up to 24 hours. Caspase 3 levels were quantified at 1, 3, 6, 9, 12, 18 and 24 
hours post DOX treatment. Results from the caspase 3 activity assay (Figure 15) 
suggested that there is apoptotic cell death occurring after DOX treatment in both MES-
SA and MES-SA/Dx5 cells. In control MES-SA and MES-SA/Dx5 cells, no difference in 
caspase 3 expression was observed; therefore, each treatment value was presented as the 
percentage increase/decrease compared to control values. An ANOVA test at each time 
point among the treatment groups indicated that 5 μM DOX treated MES-SA cells had 
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higher caspase 3 than the other three treatments at 12, 18 and 24 hour time point. 
Meanwhile, 1 μM DOX treated MES-SA/Dx5 cells had consistently lower caspase 3 
level at 12, 18 and 24 hour time point.  
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Figure 15 Caspas 3 level after DOX treatment. n =3 experiments. “*”:  statistical significance 
by comparing each treatment to control cells (cells without treatment), with one-sided Student’s 
t-test (α = 0.05). “”: statistical significance among the groups by ANOVA with bonferroni 
post-hoc correction (α = 0.05).  
The result indicated that the induction of apoptosis is dependent on DOX concentration; 
higher concentration of DOX caused more caspase 3 production. Note that due to MDR, 
1 μM of DOX did not change caspase 3 expression in MES-SA/Dx5 cells, which is 
consistent with the cytotoxicity data. Results from the DOX uptake assay (shown below) 
indicated that the low caspase 3 activation and low cytotoxicity is due to MDR 
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decreasing DOX uptake in MES-SA/Dx5 cells Furthermore, the activation of caspase 3 
depends on the DOX incubation time: longer incubation induced higher caspase 3 
expression for up to 24 hours.  
5.2 Slow Rate Incubator Hyperthermia  
5.2.1 Hoechst/PI staining  
In this set of experiments, incubator hyperthermia treated MES-SA and MES-SA/Dx5 
cells were stained with Hoechst 33342 and propidium iodide either immediately after the 
hyperthermia treatment or 24 hours post treatment in order to distinguish normal, 
apoptotic and necrotic cells. Different modes of cell death were observed at the two 
thermal doses as shown in Figures 16 & 17, which show Hoechst/PI dual staining. For all 
of the MES-SA cell images, the exposure time of Hoechst was kept at 197 ms and the PI 
channel exposure time was 347 ms; for the MES-SA/Dx5 cell images, the exposure time 
for Hoechst and PI were 223 ms and 450 ms respectively. 
Generally, mild apoptosis was observed 24 hours after the low thermal dose 1 hour 43 °C 
incubator hyperthermia; whereas the high thermal dose treatment, incubating cells for 30 
minutes at 50 °C caused necrosis. As shown in Figure 16 (a) & (d), control MES-SA and 
MES-SA/Dx5 cells showed no PI staining indicating the integrity of cell membrane; 
Hoechst staining also indicted intact cell nucleus. After 1 hour 43 °C incubation, no 
obvious change could be observed as shown by (b) & (e), except maybe one or two dead 
cells. 24 hours after the treatment, cells with fragmented blue or pink nuclei could be 
seen in both MES-SA (Figure 16 (c)) and MES-SA/Dx5 cell images (Figure 16 (f)), 
indicating these cells were undergoing apoptosis. Note that although some cells were 
undergoing apoptosis, the majority of the cells still maintained an intact cell membrane as 
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evidenced by the fact that only Hoechst staining were presented in these cells. This 
observation, combined with the cytotoxicity data presented in Figure 8, suggests that 1 
hour 43 °C incubator hyperthermia inhibited cell growth by inducing very mild apoptosis.  
Compared to 1 hour 43 °C incubation, 30 minutes 50 °C incubation caused more severe 
damage to the cells. Necrotic cell death could be seen immediately after the treatment 
(Figure 17 (a) & (c)). Although a lot of the cells were not stained by PI indicating they 
still possess an intact cell membrane at that moment, they were severely damaged by the 
heat stress and eventually died through necrosis as evident by the images taken 24 hours 
after treatment (Figure 17 (b) & (d)).                         
   
(a)                                                            (b)                                                         (c)             
                                  
                              (d)                                                             (e)                                                         (f)                    
Figure 16 Hoechst/PI staining of MES-SA (upper panel) and MES-SA/Dx5 cells (lower panel) 
treated by 1 hour 43 °C incubation. Images were taken either immediately (b&e), or 24 hours 
after the treatment (c&f) and compared to the control cells (a&d). The scale bar in (a) 
represents 8 µm. 
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                                                          (a)                                                                 (b) 
     
                                                          (c)                                                                (d) 
Figure 17 Hoechst/PI staining of MES-SA (upper panel) and MES-SA/Dx5 cells (lower panel) 
treated by 30 min 50 °C incubation. Images were taken either immediately (a&c), or 24 hours 
after the treatment (b&d) and compared to the control cells (Figure 16 a&d). The scale bar in 
(a) represents 8 µm. 
5.2.2 Quantification of caspase 3  
Since Hoechst/PI staining suggested mild apoptosis only in 1 hour 43 °C incubator 
hyperthermia treated cells and necrosis in 50 °C hyperthermia treated cells, quantitative 
caspase 3 assay was performed to 1 hour 43 °C incubator hyperthermia treated cells but 
not to 30 minutes 50 °C incubator hyperthermia treated cells. Figure 16 shows the 
caspase 3 expression in MES-SA and MES-SA/Dx5 cells treated with 1 hour 43 °C 
incubator hyperthermia. Caspase 3 levels for each cell were quantified 1, 3, 6, 12 and 24 
hours after the hyperthermia treatment and then normalized to their respective control 
which is the caspase 3 value from cells that did not receive any treatment. Since cell 
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growth was known to be inhibited 24 hours after 1 hour 43 °C incubator hyperthermia, 
the caspase 3 fluorescence values at the 24 hour time point were normalized to the SRB 
value to account for changes in cell number. Briefly, caspase 3 data after the treatment 
were normalized to the ratio of the SRB toxicity values of the treated cells to the SRB 
toxicity value of the control, which did not receive treatment. Statistical significant 
difference could be detected at 6 hours post treatment in MES-SA/Dx5 cells and 24 hours 
post treatment in MES-SA cells, but the percentage increase in caspase 3 level is only 
about 25% - 30%, indicating the extent of apoptosis is mild, which confirmed the 
observation in the Hoechst/PI staining assay.  
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Figure 18 Caspas 3 level after 1 hour 43 °C incubation, data were normalized as described 
above. n =3 experiments. “*”: statistical significance by comparing each treatment to control 
cells (cells without treatment), with one-sided Student’s t-test (α = 0.05). 
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5. 3 Rapid Rate Laser-ICG Hyperthermia 
5.3.1 Hoechst/PI staining  
In both MES-SA and MES-SA/Dx5 cells, laser-ICG hyperthermia induced necrosis at 
both 5 μM and 10 μM ICG concentration as shown in Figures 19 & 20. Cells were treated 
with 5 µM or 10 µM of ICG and excited with NIR laser for 3 minutes, which produced 
43 °C and 50 °C hyperthermia respectively. The images were taken either 1 or 24 hours 
after the NIR irradiation. This 1 hour time point was chosen because the laser irradiation 
was only 3 minutes, therefore images were taken 1 hour after the treatment in order to be 
able to compare with the 1 hour incubator hyperthermia treatment. In control cells, which 
did not receive any treatment, only Hoechst staining can be seen as PI cannot penetrate an 
intact cell membrane. With the increase of thermal dose (more ICG) the fluorescence of 
PI increased indicating more severe cell membrane damage. For all the MES-SA cell 
images the exposure time of Hoechst was kept at 143 ms and the PI channel exposure 
time was 332 ms; for the MES-SA/Dx5 cell images, the exposure time for Hoechst and PI 
were 197 ms and 450 ms respectively; 
In the previous section, mild apoptosis in both MES-SA and MES-SA/Dx5 cells 24 hours 
after the slow rate 1 hour 43 °C incubator hyperthermia are shown. Here it is shown that, 
when the heating is rapid, the same thermal dose (5 µM ICG + 3 minute laser) caused cell 
necrosis instead of apoptosis in 24 hours, as evident by Figure 19 (c) & (f). Similar to the 
1 hour 43 °C incubation treatment, there is no significant morphological change 
immediately after 5 µM laser-ICG hyperthermia. 
When comparing the mode of cell death at the higher thermal dose, the similarity is that 
both slow rate (incubator) and rapid rate (3 minute laser + 10 µM ICG) hyperthermia lead 
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to necrosis in almost all the cells 24 hours after hyperthermia treatment (Figure 20 (b) & 
(d)). However, the effect of the rapid rate laser-ICG hyperthermia is also more rapid 
because it caused complete cell necrosis immediately after the treatment (Figure 20 (a) & 
(c)) whereas there are still some cells possessing intact cell membrane immediately after 
the 30 minutes 50 °C incubation as shown in Figure 17 (a) & (c).  
   
                             (a)                                                            (b)                                                         (c) 
   
                       (d)                                                           (e)                                                          (f)    
Figure 19 Hoechst/PI staining of MES-SA (upper panel) and MES-SA/Dx5 cells (lower panel) 
treated by laser excited (3 min) ICG (5 μM). Images were taken either immediately (b&e), or 24 
hours after the treatment (c&f) and compared to the control cells (a&d). The scale bar in (a) 
represents 8 µm.  
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                                             (a)                                                                (b) 
     
                                            (c)                                                                  (d) 
Figure 20 Hoechst/PI staining of MES-SA (upper panel) and MES-SA/Dx5 cells (lower panel) 
treated by laser excited (3 min) ICG (10 μM). Images were taken either immediately (a&c), or 
24 hours after the treatment (b&d) and compared to the control cells (Figure 22 a&d). The 
scale bar in (a) represents 8 µm. 
5.3.2 Quantification of caspase 3 
Figure 21 shows the caspase 3 expression in MES-SA and MES-SA/Dx5 cells treated 
with laser-ICG hyperthermia. Cells were incubated with 5 μM of ICG and excited with 
NIR laser for 3 minutes to produce a 43 °C hyperthermia. Caspase 3 levels were 
quantified 1, 3, 6, 12 and 24 hours after the hyperthermia treatment and then normalized 
to their respective control, the values from cells that did not receive any treatment. Since 
cell growth was known to be inhibited 24 hours after the hyperthermia treatment, the 
caspase 3 fluorescence values at the 24 hour time point were normalized to the SRB 
toxicity values to account for changes in cell number. Briefly, the caspase 3 values after 
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the treatment were normalized to the ratio of the SRB toxicity values of treated cells to 
the control, which are the SRB toxicity values from cells that did not receive treatment. 
No significant apoptosis could be detected in both MES-SA and MES-SA/Dx5 cells after 
up to 24 hours post treatment.  
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Figure 21 Caspas 3 level in MES-SA and MES-SA/Dx5 cells treated with 5 μM ICG and 
irradiated by laser for 3 minutes. Data were normalized as described above. The final 
temperature was 43 °C.  n =3 experiments.    
6. DOX Uptake  
Figures 22-23 show the DOX fluorescence intensity and subcellular localization in 
incubator hyperthermia treated MES-SA and MES-SA/Dx5 cells respectively. Images 
were taken either immediately after the hyperthermia treatment or 24 hours post 
treatment. The exposure time for the DOX signal was kept at 1000 ms for all the images.  
 81
Generally, the DOX fluorescence intensity increased with increasing incubation time in 
both cell lines, as the images taken 24 hours after the treatment were brighter than the 
ones taken immediately after the treatment.  
For MES-SA cell, the fluorescence intensity and subcellular localization of DOX did not 
change significantly after the incubator hyperthermia treatment, which is reasonable 
because MES-SA is DOX sensitive and DOX can diffuse freely into the cell, therefore, 
the facilitating effect of hyperthermia to DOX is not obvious.  
Compared to MES-SA, DOX showed a different subcellular localization pattern in MES-
SA/Dx5 cells. As shown in Figure 23 (b), the cell membrane was stained by the DOX 
fluorescence while the nucleus compartment was dark. This is because the P-gp pump 
was anchored in the cell membrane of MES-SA/Dx5 cells and any DOX molecule 
attempting to diffuse through it was captured and pumped out. Meanwhile, facilitated 
DOX uptake by incubator hyperthermia was obvious in MES-SA/Dx5 cells. DOX 
fluorescence intensity increased with the increase of thermal dose both immediately after 
the treatment (DOX fluorescence intensity: (e) > (c) > (a)), and 24 hours after the 
treatment (DOX fluorescence intensity: (f) > (d) > (b)).  
Although more DOX accumulated in the MES-SA/Dx5 cell after 1 hour 43 °C incubation 
(Figure 23 (c) & (d)), the subcellular localization of DOX did not change compared to the 
DOX only treatment (Figure 23 (b)), indicating the P-gp pump activity was not 
compromised. The increased DOX fluorescence intensity could be due to increased cell 
membrane permeability or increased DOX diffusion rate under hyperthermia condition.  
Different DOX subcellular localization was observed in 30 minutes 50 °C incubator 
hyperthermia treated cells. As shown by Figure 23 (e) & (f), most cells showed nucleus 
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staining.  From the Hoechst/PI staining presented in Figure 17 (c), after 30 minutes 50 °C 
incubator hyperthermia, a large portion of the cells maintained membrane integrity as 
they showed only Hoechst fluorescence, thus, the cell nucleus staining shown in Figure 
23 (f) suggests that P-gp pump activity was compromised immediately after the treatment. 
  
                                                             (a)                                                           (b) 
  
                                                             (c)                                                           (d) 
  
                                                             (e)                                                            (f)   
Figure 22 DOX fluorescence in MES-SA cell treated by only DOX (a&b), DOX + 1 hour 43 °C 
incubation (c&d), and DOX + 30 minutes 50 °C incubation (e&f). Images were taken either 
immediately (a, c & e), or 24 hours after the treatment (b, d & f). The scale bar in (a) 
represents 8 µm. 
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                                                             (a)                                                           (b) 
  
                                                             (c)                                                           (d) 
  
                                                             (e)                                                            (f)   
Figure 23 DOX fluorescence in MES-SA/Dx5 cell treated by only DOX (a&b), DOX + 1 hour 
43 °C incubation (c&d), and DOX + 30 minutes 50 °C incubation (c&d). Images were taken 
either immediately (a, c & e), or 24 hours after the treatment (b, d & f). The scale bar in (a) 
represents 8 µm. 
Figures 24-25 show the DOX fluorescence intensity and subcellular localization in laser-
ICG hyperthermia treated MES-SA and MES-SA/Dx5 cells respectively. Images were 
taken either 1 hour after the hyperthermia treatment (in order to compare with incubator 
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hyperthermia) or 24 hours post treatment. The exposure time for the DOX signal was 
kept at 1000 ms for all the images.  
Generally, the DOX fluorescence intensity increased with increasing incubation time in 
both cell lines, as the images taken 24 hours later were brighter than the ones taken 
immediately after the treatment.  
For MES-SA cell, the subcellular localization of DOX did not change because they are 
DOX sensitive and DOX mainly binds to the DNA, thus the cell nucleus brightness was 
enhanced. Previously, we have shown that incubator hyperthermia treatment did not 
increase DOX uptake significantly in MES-SA cell. Here increased DOX fluorescence 
intensity indicating increased DOX retention after the laser-ICG hyperthermia was 
observed, probably because laser-ICG hyperthermia caused more severe cell membrane 
damage than the incubator hyperthermia as evident by the Hoechst/PI staining.  
Similar to the incubator hyperthermia treated MES-SA/Dx5 cell, facilitated DOX uptake 
was obvious also by the laser excited ICG (5 μM) hyperthermia. DOX fluorescence 
intensity increased with the increase of thermal dose both immediately after the treatment 
(DOX fluorescence intensity: (e) > (c) > (a)), and 24 hours after the treatment (DOX 
fluorescence intensity: (f) > (d) > (b)).  
We have shown that 1 hour 43 °C hyperthermia did not change P-gp pump activity in 
MES-SA/Dx5 cells. However, at the same thermal dose, the rapid rate laser-ICG 
hyperthermia caused DOX accumulation in the cell nucleus. As shown in Figure 25 (d), 
only a few cells showed dark cell nucleus probably due to severe cell membrane damage 
as evident by the Hoechst/PI assay shown in Figure 20 (c). At higher thermal dose (10 
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μM ICG), DOX fluorescence was present in almost all the cells, which is similar to the 
incubator hyperthermia at the same dose.   
  
                                                             (a)                                                           (b) 
  
                                                             (c)                                                           (d) 
  
                                                             (e)                                                            (f)   
Figure 24 DOX fluorescence in MES-SA cell treated by only DOX (a&b), DOX + 3 min laser/5 
μM ICG (c&d), and DOX + 3 min laser/5 μM ICG incubation (e&f). Images were taken either 
immediately (a, c & e), or 24 hours after the treatment (b, d & f). The scale bar in (a) 
represents 8 µm. 
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                                                             (a)                                                           (b) 
  
                                                             (c)                                                           (d) 
  
                                                             (e)                                                            (f)   
Figure 25 DOX fluorescence in MES-SA/Dx5 cells treated by only DOX (a&b), DOX + 3 min 
laser/5 μM ICG (c&d), and DOX + 3 min laser/5 μM ICG incubation (e&f). Images were taken 
either immediately (a, c & e), or 24 hours after the treatment (b, d & f). The scale bar in (a) 
represents 8 µm. 
When comparing the rapid rate laser-ICG hyperthermia to the slow rate incubator 
hyperthermia, they both exhibited the ability to overcome P-gp at high thermal dose; 
however, at low thermal dose, the laser-ICG hyperthermia showed its superiority in 
helping DOX bypass P-gp mediated MDR as more DOX were presented in cell nucleus. 
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7. P-gp Activity  
From the results of pervious experiments, we can see an increased DOX fluorescence 
indicating facilitated uptake during hyperthermia condition in both MES-SA and MES-
SA/Dx5 cells. However, the reason for this increase in DOX uptake is not clear. We 
performed P-gp activity assay to find out whether this increase is due to the inhibition of 
p-gp drug efflux pump activity in the MES-SA/Dx5 cell. The calcein-AM assay was used 
to determine if the increased permeability can help drugs bypass the P-gp MDR system. 
    
                             (a)                                                         (b)                                                            (c)       
Figure 26 Calcein fluorescence after hyperthermia treatment. (a) MES-SA without any 
treatment; (b) MES-SA treated by 1 hour 43ºC incubator hyperthermia; (c) MES-SA treated 
with verapamil.  Exposure time 1000 ms. The scale bar in (a) represents 24 µm. 
MES-SA cells do not overexpress P-gp, thus, calcein-AM can diffuse freely into the cell 
and be cleaved to form bright green fluorescence. As shown in Figure 26 (c), the 
induction of P-gp inhibitor verapamil does not increase calcein fluorescence compared to 
the control. Meanwhile, 1hour 43 ºC incubator hyperthermia did not change P-gp activity 
as well, as evident by Figure 26 (b). 
For the MES-SA/Dx5 cells, since it highly overexpresses P-gp, calcein-AM does not 
remain intracellular, as evident by the low fluorescence in Figure 27 (a). In Figure 27 (d), 
MES-SA/Dx5 cells were treated with the P-gp inhibitor verapamil; therefore, calcein-AM 
entered the cell and was cleaved to form fluorescent calcein. Figure 27 (b) showed that 1 
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hour 43 ºC incubator hyperthermia did not reduce P-gp activity as fluorescence signal 
was weak and similar to the control cell which did not receive any treatment. The laser 
exposure to 5 μM ICG for 3 minutes, on the other hand, caused a slight increase in 
calcein-AM fluorescence which is consistent with what was seen in the DOX uptake 
study. This assay indicated that the rapid rate laser-ICG hyperthermia can achieve better 
P-gp inhibition than the slow rate incubator hyperthermia.  
          
                              (a)                                                     (b) 
         
                                          (c)                                                      (d) 
Figure 27 Calcein fluorescence after hyperthermia treatment. (a) Dx5 cell without any 
treatment; (b) Dx5 cell treated by 1h 43ºC incubator hyperthermia; (c) Dx5 cell treated by 5 
μM ICG + 3 min laser; (d) Dx5 treated with verapamil. All the images were taken under 20X 
magnification and the exposure time was 1000 ms. The scale bar in (a) represents 24 µm. 
VI. DISCUSSION 
1. The Induction of Thermotolerance  
In specific aim 1, it is hypothesized that the rate of heating is a determinant factor in cells 
acquiring thermal tolerance, which is more likely to occur in low dose hyperthermia with 
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longer exposure time. Therefore, it was proposed that the rapid rate NIR laser-ICG 
hyperthermia could avoid the induction of thermal tolerance because the duration of 
treatment is short while the slow rate incubator hyperthermia could cause thermal 
tolerance induction. This hypothesis is supported by the results from the HSP70 ELISA 
assay where the HSP70 level after 1 hour 43 ºC hyperthermia was significantly higher 
than the non-treated control cells while at the same thermal dose, the rapid rate 3 minute 
laser + 5 μM ICG hyperthermia did not cause any increase compared to the controls. This 
difference suggested the importance of the rate of heating because thermotolerance 
obviously developed to a greater degree during slow heating rates when the temperature 
of hyperthermia was near the breakpoint. A breakpoint temperature (usually around 43 ºC) 
is where cytotoxicity of hyperthermia starts to occur. Below the breakpoint, cells can 
survive under even extended hyperthermia through overexpressing HSPs.  
It has been discovered by both in vitro and in vivo studies that a rapid rate of heat 
accumulation can reduce cell survival or increase thermal injury [110-112]. In this regard, 
some researchers have already tried to correlate cellular HSP70 level as the biomarker of 
thermotolerance with different heating rates but none of them had achieved positive 
results.  
In 1995, Flanagan et al. [110] found that HSP70 level was significantly higher after a 
rapid rate hyperthermia but not increased after a slow one, a result opposite to ours. The 
reason for this difference could be that their heating is too slow, even in the rapid rate 
heating. In their study, the rapid rate was chosen at 0.166 ºC/min, a rate that is similar to 
the slow rate (0.1 ºC/min) used in this study. As a comparison, the rapid rate heating 
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employed in this study was about 4 ºC/min. From this point of view, their result 
supported our conclusion.  
In early research conducted by Burns et al. [111] gradually heated L1210 leukemia cells 
did not overexperss HSP70, while increased HSP70 synthesis was observed in rapidly 
heated cells. However, their experiment had a similar problem to Flanagan’s, that is, the 
thermal dose in the slow rate heating was much higher than in the rapid rate heating.     
Since thermal tolerance is dependent on thermal dose, it is crucial to keep thermal dose 
constant when studying the effect of heating rates on the induction of thermal tolerance. 
My study showed for the first time that slow rate heating is more likely to induce thermal 
tolerance than a rapid rate heating when the thermal dose is similar.   
2. Thermal Resistance and Drug Resistance  
The HSPs are a family of highly conserved stress proteins present in the cells of all living 
organisms [113]. It could be found to be expressed at very low levels in healthy cells to 
help newly synthesized proteins to fold to an appropriate special conformation. Its 
expression can increase not only when cells are under heat stress but also due to other 
stresses such as infection, inflammation, or toxins exposure [114]. Our observation that 
the baseline HSP70 level in MES-SA/Dx5 cells was two times higher than in MES-SA 
cells suggests that the induction of MDR might induce HSP70 overexpression. MES-
SA/Dx5 cells are developed by incubating DOX sensitive MES-SA cells with stepwise 
increased concentration of DOX, which is a serious stress condition to the cells.  It has 
long been discovered that the induction of thermal tolerance can simultaneously increase 
drug resistant. Tumor cells sequentially exposed to nonlethal hyperthermia and then 
chemotherapy showed higher cell survival than when the two were given simultaneously 
 91
[115, 116]. Pirity et al. [117] conducted research with rat hepatoma and observed that 
cells which were induced to overexpress P-gp did not overexpress HSPs, whereas cells 
which were induced to overexpress HSPs showed increased level of P-gp. These results 
suggested that hyperthermia should not be given prior to chemotherapy in order to avoid 
heat induced MDR, however, none of these findings can explain the increased baseline 
HSP70 expression in MDR positive MES-SA/Dx5 cells. Recently, Tchénio et al. [118] 
successfully isolated heat shock factor 1 (HSF1) transcription factor, which regulates the 
expression of the HSPs, in cultured human U2-OS osteosarcoma cells that confer DOX 
resistance. Their results indirectly supported our observation in MES-SA/Dx5 cells that 
drug resistance might increase cell’s thermal tolerance.  
3. Apoptosis in DOX Chemotherapy  
DOX can cause apoptotic cell death through several distinct mechanisms [93]. DOX 
induced apoptosis had been reported in various cell lines and with a wide range of 
concentrations [119-123]. In a study conducted by Angelini et al. [124], 5 µM and 10 µM 
DOX concentration induced apoptosis in MES-SA/Dx5 cells. Moreover, they observed 
increasing apoptosis with increasing DOX intracellular accumulation, which to some 
extent supports the data presented in this study. In the current study, 1 µM DOX induced 
apoptosis in DOX sensitive MES-SA cells but not in DOX resistant MES-SA/Dx5 cells 
probably because the intracellular DOX concentration in MES-SA cells is much higher 
than in MES-SA/Dx5 cells due to the P-gp pump in the MES-SA/Dx5 cells. 
4. Mode of Cell Death by Hyperthermia 
As has been mentioned previously, hyperthermia is capable of inducing apoptosis or 
necrosis depending on the temperature/thermal dose [125]. Generally, above the 
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“breakpoint” temperature, cancer cells start to die because of heat stress. With the 
increase of temperature, the percentage of apoptotic cells decreases with a concomitant 
increase in necrotic cells [29, 126]. Some other factors can slightly affect this response 
process, such as cell type, stage of cell cycle and prior exposure to heat [1, 29, 127].  
In specific aim 2, we have hypothesized that other than temperature/thermal dose, 
differences in heating rates can lead to different modes of cell death. More specifically, 
moderate slow rate hyperthermia at 43 °C induced by the incubator is not enough to exert 
necrosis; indirect cellular damage is most likely and apoptotic cell death results from this 
indirect process; while in the rapid rate 43 °C NIR laser-ICG hyperthermia, necrotic cell 
death is expected through protein denaturing caused by rapid heat accumulation at the 
ICG bound cellular proteins. Meanwhile, at 50 °C, both slow rate incubator hyperthermia 
and rapid rate laser-ICG hyperthermia should lead to necrotic cell death.  
The results of the Hoechst/PI assay on the 50 °C treated cells support the hypothesis 
made in specific aim 2 since the two hyperthermia treatments caused complete necrosis 
both immediately or 24 hours after treatment, which is consistent with what was reported 
in the literature. The result of the Hoechst/PI assay on the 43 °C treated cells suggest that, 
at the same temperature and thermal dose, rapid rate laser-ICG hyperthermia results in 
necrosis while slow rate incubator hyperthermia results in apoptosis, which also support 
the hypothesis made in specific aim 2. Moreover, it indicates for the first time that 
necrotic cell death could be induced at a temperature that typically would cause apoptosis 
as long as the rate of heating is rapid. Since a variety of cancer cells have an impaired 
apoptosis pathway, the ability to induce necrosis by the rapid rate heating at 43 °C 
provide us more opportunity to treat cancers that are resistant to apoptosis. 
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An inconsistence in the apoptosis assay results was also observed. In the 50 °C 
hyperthermia, cellular caspase 3 levels were found to be decreased after both rapid rate 
and slow rate hyperthermia treatment, probably because the number of cells decreased 
significantly due to the extremely high thermal dose. The assay could be more accurate if 
it were coupled with a cell viability assay.  
5. DOX-hyperthermia Synergism and Clinical Prospect  
Although DOX is considered one of the most effective anticancer agents [128], its 
clinical use is restricted due to its side effect of inducing cardiomyopathy and congestive 
heart failure, which is cumulative and irreversible [129]. In order to increase its 
therapeutic effect as well as minimize its cardiotoxicity to cancer, considerable research 
has been conducted. Second-generation DOX analogs like epirubicin or idarubicin 
showed improved therapeutic index over DOX, but the side effect of cardiotoxicity still 
exists [130]. Besides its side effect, MDR induction in tumor is another major obstacle to 
DOX chemotherapy. In order to overcome MDR, drug carriers such as liposomes have 
been used. Pegylated liposomal DOX has been clinically used to treat advanced ovarian 
cancer [94]. However, its improvement in response rate was not satisfying (the response 
rate was less than 30%) [94].  
In specific aim 3 it was hypothesized that a synergistic effect may exist when combining 
DOX chemotherapy with the rapid rate hyperthermia, especially in the MDR MES-
SA/Dx5 cells. Results from the cytotoxicity assay generally support this hypothesis; 
furthermore, this synergistic effect is due to increased uptake of DOX and the reversal of 
MDR as evident by the DOX fluorescence imaging. Therefore, by applying rapid rate 
hyperthermia to DOX chemotherapy, a significant reduction in the overall patient dose 
 94
could be achieved in order to reach the same therapeutic effect compared to when using 
DOX alone, thus the side effect of DOX could be minimized. More importantly, rapid 
rate hyperthermia could be a safe approach to help DOX overcome MDR. 
VII. CONCLUSION 
It has been recognized for years that synergetic cancer cell killing can be achieved by 
simultaneously deliver of chemotherapy and hyperthermia. This in vitro study in cultured 
cancer cells shows that the potentiating effect of hyperthermia to chemotherapy can be 
maximized by increasing the rate of heating as evident by the results from the 
cytotoxicity assay. When delivered at the same thermal dose, rapidly increasing 
temperature from 37 °C to 43 °C caused more cell membrane damage than gradually 
heating the cells from 37 °C to 43 °C and thus allowed for more intracellular 
accumulation of the chemotherapeutic agents DOX. Different modes of cell death were 
observed under low thermal dose hyperthermia by the two hyperthermia delivery 
methods. The rapid rate laser-ICG hyperthermia @ 43 °C caused cell necrosis whereas 
the slow rate incubator hyperthermia @ 43 °C induced very mild apoptosis. At 43 °C a 
positive correlation between thermal tolerance and the length of hyperthermia exposure 
was identified. More importantly, this study shows that by increasing the rate of heating, 
less thermal dose is needed in order to overcome P-gp mediated MDR.  
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APPENDICES 
General Protocol for Preparing and Filtering Medium 
Preparing medium 
1) Start the hot water bath and set its temperature to 37°C. 
2) Take the Penicillin and FBS (fetal bovine serum) from the freezer and the required 
Medium brand from the refrigerator. Insert them in the hot water bath at 37°C. (Note: to 
avoid repeated freezing and thawing, penicillin and FBS aliquots of predetermined 
volume must be made and stored in the freezer) 
3) When the penicillin, FBS and medium are sufficiently warm, take them out and spray 
them with alcohol. Let it air dry and place them in the Laminar Flow Hood. 
4) Insert a Medium Filter bottle in the Laminar Flow Hood after spraying with alcohol. 
5) Add 5mL of Penicillin + 50mL of FBS + 445mL of Medium, to the filter bottle. (Note: 
these volumes are dependant on the Complete Growth Medium requirement of the cell 
lines used which may vary) 
Filtering the medium 
1) Connect the filter bottle to a vacuum. Make sure the vacuum “switch” is off when 
connecting. 
2) Upon opening the vacuum switch, the liquid from the bottle is filtered and transferred 
to an adjoined container. Separate the adjoined container and cap it. 
3) Label the container “filtered medium + penicillin, FBS, name, date”. Store container in 
the refrigerator. 
4) Any remaining penicillin and FBS can be store in the freezer. 
General Protocol for Cell Culturing 
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Day n 
1) Place the medium in a water bath to bring up its temperature to 37°C. 
2) When the medium is ready, spray it with alcohol and place it in the laminar flow hood. 
Make sure that the sterile flaks and all necessary accessories are already in the hood. 
3) Add 12mL or 4.5mL of medium to the 250mL or 50mL culture flask respectively. 
4) Obtain a cryo-vial with the appropriate cell line from the liquid nitrogen freezer. 
5) Wrap the mouth of the vial with a paraffin film. These vials should then be quickly 
thawed by immersing the bottom half of the vial in the 37°C water bath and gently 
stirring it. 
6) When the vial is thawed, take it to the laminar flow hood; gently pipette the contents of 
the vial up and down once. Then add all of the vial contents (~1.8mL) to the 250mL 
culture flask already containing the media. If using the 50mL culture flask, add ~1mL of 
the content of the vial to culture flask and repeat with another 50mL flask for the 
remainder of the vial contents. (Note: it is preferable to culture cancer cell lines in the 
250mL flasks as they become confluent sooner than normal cell lines; also if the cancer 
cell density of the cryo-vial is high then the vial contents can be split equally in two 
250mL culture flasks; for cell lines such as the HUVEC, add all the contents of the vial to 
the 50mL flask as the HUVECs grow slower compared to the cancer cell lines.) 
7) Label the flask (Medium+Cell line, Name, Date). 
8) Put this flask in the incubator for 4 hours. (Note: for cell lines like the HUVEC, 24 
hours should be used instead for this step.) 
9) After 4 hours, change the medium in the cell culture flask, by removing the old 
medium and adding 12mL or 4.5mL of new medium depending on the flask size. 
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Day n+3 
1) Put the medium and trypsin in hot water bath. Make a beaker labeled waste, spray with 
alcohol and put them in the laminar flow hood. 
2) In the Laminar flow hood, take out the spent medium from the 250mL culture flask 
labeled “medium + cells” via pipette, and dispose in the beaker labeled “waste”. 
3) Pipette 4mL of trypsin and add it to the 250mL culture flask, gently shake it. (Note: for 
the 50mL culture flask add 2mL of trypsin.) 
4) Remove the trypsin, dispose it in the beaker labeled “Waste”. 
5) Repeat steps 3, but leave flask with the trypsin in the incubator for 5-10 minutes, keep 
monitoring the culture flask in the microscope to make sure cells are detaching. 
6) In the meantime prepare a new 250mL culture flask with 12mL of fresh medium. 
(Note: use 4.5mL of medium for the 50mL flask.) 
7) When the cells seem to detach, take out 10uL of the trypsin + cell solution (from the 
trypsinized flask), and use it in the hemocytometer to get an average count of cell density 
per mL. (Note: depending on the cell density, one can choose to reduce the cell 
concentration in the trypsinized culture flask by adding fresh medium.) 
8) Take 1mL of the cell solution (cell+trypsin) from the trypsinized flask and pipette 
them in a new flask consisting of 12mL or 4.5mL of fresh medium depending on the 
Flask size. Label and incubate them for future use. The rest of the cell solution can be 
used for seeding in 96-well plates. 
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General Protocol for Seeding Culture Cells 
1) After the cells have been counted in the hemocytometer, calculate the required 
concentration of the cell solution for seeding in the 96-well plates. (Note: this can be 
between 5000-10000 cells per well depending on the experimental design.) 
2) Depending on the above calculation mix the cell solution with the appropriate volume 
of fresh medium in a pipette basin. 
3) Take three 96-well plates and label them A, B and C. 
4) Use a multipipetter and mix the cell solution + fresh medium mixture in the basin by 
pipetting in and out into the basin a few times. (Note: From this point onwards the cells 
can be seeded using a multipipetter in any number of combinations in different well 
plates depending upon the experimental design) 
5) After this use the multipipetter to pipette 200uL of the basin solution into 8 wells (8 
rows of column 2) in plate A simultaneously. Then repeat this for plate B and C. Make 
sure to leave column 1 empty for the time being. 
6) Then repeat step 5 in column 3 for plates A, B and C. 
7) Keep on repeating until column 6 (depending on the experimental design) of plates A, 
B and C is filled with the basin solution. 
8) Use the multipipetter to add fresh medium in column 1 for all the three plates. 
9) Incubate the 96-well plates at 37°C. 
General Protocol for SRB Assay 
1) When the cells in the 96 well plates are ready for the assay, put TCA in the refrigerator 
for 40 min. 
2) When the TCA is ice cold, add 50μL of TCA to each well. 
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3) Wrap the plate in foil paper and put the well plate in the fridge for 1 hour. 
4) After 1 hour, rinse the plate with De-ionized water and let it air dry. 
5) Add 100μL of SulfoRhodamine B solution (SRB Dye-purple dye) and let it stain for 
20-30 minutes. 
6) Rinse the plate 3 times with 1% Acetic Acid (you might need to dilute the Acetic Acid 
in distilled water). Let it air dry. 
7) Add 200μL of Tris Base solution into the wells; let it sit for 5 minutes. Make sure that 
the SRB is thoroughly dissolved in the Tris Base. (Note: allow more than 5 minutes to 
dissolve if the need arises so) 
8) Put the plate in the Tecan machine. 
9) On the Computer, follow: Tecan--RdrOle4--Instrument--Connect. 
Tecan--Magellan--Insert--Measurement Parameter: select part of the plate where cells are 
(ex. A1:D5), Measurement 530:690 Kinetics N., Shaking (check) 60 sec. 
Instrument--Start measurement. 
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